Rev. 01/06/14

1

Rev. 01/06/14

Fl Nme: LockeyCV3of3

Book

Chapters

1. Lockey RF, Bukantz SC:

Allergic Emergencies.

Med Clin North Am 58:147-156, 1974.


Urgencias Alergicas.

Clinicas Medicas de Norteamerica, Alergia en adultos,

Enero – pp 174-196, 1974.


Diagnostic Tests and Hyposensitization Therapy in Asthma.

In: Bronchial asthma, Mechanisms and Therapeutics.

Weiss EB, Segal MS (eds).

Little, Brown and Co, Boston, pp 613-637, 1976.

4. Lockey RF:

Immunopathologic (allergic) Mechanisms.

In: Allergy and Clinical Immunology.

Lockey RF (ed).

Medical Examination Publishing Co, Inc. Garden City,

New York, pp 121-140, 1979.


Allergic Emergencies.


Lockey RF (ed).

Medical Examination Publishing Co, Inc, Garden City,

New York, pp 906-918, 1979.

6. Lockey RF:

Glucocorticosteroids in Treatment of Asthma and Allergic

Disease.


Lockey RF (ed).

Medical Examination Publishing Co, Inc, Garden City,

New York, pp 957-976, 1979.

7. Lockey RF:

Member of Panel on Allergic Emergencies, U.S.

Department of Health, Education and Welfare. NIAID

Task Force Report:

Asthma and the Other Allergic Diseases.

NIH publication 79-387, May, 1979.

2


Allergy and Asthma.

In: Sodeman’s Pathologic Physiology, Mechanisms of Disease.

Sodeman WA, Sodeman TM (eds).

WB Saunders, Philadelphia, pp 507-527, 1979.

9. Parrino J, Lockey RF:

Allergic Reaction to Insect Stings.

In: Current Therapy.

Conn HR (ed).


10. Lockey RF:

Allergic and Other Adverse Reactions Caused by the Imported fire

Ant.

In: Advances in Allergology and Applied Immunology,

Oehling A, Glazer I, Mathov E, Arbesman C (eds).

Pergamon Press, Oxford, pp 441-448, 1980.

11. Lockey RF, Stablein JJ:

Ants and Human Anaphylaxis.

In: Monograph on Insect Allergy.

Levine M, Lockey RF (eds).

AAAAI, Milwaukee, Wisconsin, pp 61-67, 1981.

12. Bukantz SC, Lockey RF, Fenske NA, Donelau PA, Flowers FP:

Allergy, Immunology, Dermatology.

In: Sodeman's Self-Assessment of Current Knowledge in Internal Medicine, Sixth

Edition, Chapter 7.

Medical Examination Publishing Company, New Hyde Park,

New York, pp 82-9, 1982.

13. Fox RW, Lockey RF:

Immediate Hypersensitivity and Immune Complex Disease.

In: Circulating Immune Complexes in Clinical Medicine.

Espinoza LR, Osterland CK (eds).

Futura Publishing Co, New York, New York, pp 295-319, 1982.

14. Lockey RF, et al:

Primer on Allergic and Immunologic Diseases.

Contributor.

Journal of the American Medical Association 248, 1983.

15. Lockey RF:

Allergic Reactions to Insect Stings.

In: Conn's Current Therapy.

Rakel RE (ed).

WB Saunders, Philadelphia, pp 592, 1984.

16. Samaan SS, Fox RW, Bukantz SC, Lockey RF:

Comparison of Diurnal and Nocturnal Theophylline Levels at Steady-State

In: Annual Review of Chronopharmacology.

Rembing A, Smolensky M, Labresque G (eds).

Pergamon Press, New York, volume 1, pp 69-72, 1984.

3

17. Lockey RF:



Rakel RE (ed),


18. Stablein JJ, Lockey RF:

Ants and Human Anaphylaxis.

In: Monograph on Insect Allergy.

Levine ME, Lockey RF (eds).

American Academy of Allergy and Immunology.

Dave Lambert Associates, Pittsburgh, Pennsylvania, pp 75-82, 1986.


The Role of Immunotherapy in Asthma.

In: Bronchial Asthma, Second Edition.

Gershwin ME (ed).

Grune and Stratton, Inc., Orlando, Florida, pp 371-392, 1986

20. Samaan SS, Fox RW, Bukantz SC, Lockey RF:

The Effects of Age and Circadian Rhythm on Theophylline Pharma-1 Kokinetics in

Normal Subjects. In: Current Treatment of Ambulatory Asthma.

Settipane GA (ed). New England and Regional Allergy Proceedings, Providence, RI,

pp 87-91,1986.

21. Lieberman P, Stablein JJ, Lockey RF:

Drug Allergy.

In: Allergy, An International Textbook.

Lessof MH, Lee TH, Kemeny DM (eds).

John Wiley and Sons, New York, pp 381-408, 1987.

22. Calderon E, Ramirez MA, Arrieta MI, Fernandez-Caldas E, Russell D, Lockey RF:

Nutritional Disorders in HIV Disease.

In: Food and Nutrition Science,

Chandra RK (ed).

Pergamon Press, Vol.14: 371-402, 1990.

23. Fernandez-Caldas E, Reed C, Lockey R:

Distribution of Indoor Allergens.

In: Allergen Immunotherapy.

Lockey R, Bukantz S (eds).

Marcel Dekker, Inc., New York, pp 69-102, 1991.


Allergen Immunotherapy Side Effects.

In: Allergen Immunotherapy.

Lockey RF, Bukantz SC (eds).

Marcel Dekker, Inc., New York, pp 233-264, 1991.

25. Lockey RF:



Rakel RE (ed).

W. B. Saunders, Philadelphia, pp 712-715, 1992.

4

26. Bucholtz G, Fernandez-Caldas E, Lockey RF:

Allergic Rhinitis Caused by House Dust and other Non Pollen Allergens.

Lichtenstein L, Fauci T (eds).

In: Current Therapy in Allergy, Immunology, and Rheumatology, B.C. Decker, Inc.,

pp 7-11, 1992.

27. Bukantz SC, Lockey RF:

IgE Immediate Hypersensitivity.

In: Bronchial Asthma: Mechanisms and Therapeutics.

Weiss EB, Stein M (eds).

Little, Brown and Co, Boston, pp 68-79, 1993.

28. Fernandez-Caldas E, Garcia-Ramos E, Calderon E, Lockey RF:

Antecedentes Historicos, Alergenos y Mecanismos Immunologicos de las

Enfermedades Alergicas.

In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respiratorias En

Tenerife.

Consejeria de Sanidad, Trabajo y Servicios Sociales, Gobierno Autonomo de

Canarias, 1994.

29. Garcia-Ramos E, Fernandez-Caldas E, Calderon E, Lockey RF:

Asma y Rinitis Alergica: Epidemiologia, Diagnostico, Tratamiento y Control

Ambiental.

In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respira-torias En

Tenerife.

Consejeria de Sanidad, Trabajo y Servicios Sociales,Gobierno Autonomo de

Canarias, 1994.

30. Fernandez-Caldas E, Garcia-Ramos E, Calderon E, Lockey RF:

Alergias Respiratorias en Tenerife.

In: Epidemiologia Y Factores Desencadenantes De Las Alergias Respiratorias En

Tenerife.

Consejeria de Sanidad, Trabajo y Servicios Sociales, Gobierno Autonomo de

Canarias, 1994.


Adverse Effects and Fatalities Associated with Immunotherapy and Skin Testing.

In: Immunotherapy: A Practical Guide to Current Procedures. Creticos PS (ed),

Lockey RF (assoc ed).

American Academy of Allergy and Immunology, Milwaukee, Wisconsin,

pp 8:1-6, 1994.

32. Lockey RF, Portnoy JM, Creticos PS:

Forms Used for Skin Testing and Immunotherapy.

In: Immunotherapy: A Practical Guide to Current Procedures.

Creticos PS (ed), Lockey RF (assoc ed).

American Academy of Allergy and Immunology, Milwaukee, Wisconsin,

pp 7:1-72, 1994.


The Role of Immunotherapy in Asthma.

In: Bronchial Asthma: Principles of Diagnosis and Treatment.

Gershwin ME, Halpern GM (eds).

Humana Press, Totowa, NJ, pp 365-398, 1994.

5

34. Ledford DK, Lockey RF:

Imunotherapy for Allergic Disease.

In: Allergy, Asthma, and Immunology from Infancy to Adulthood, Third Edition.

Bierman CW, Pearlman DS, Shapiro GG, Busse WW (eds).

W. B. Saunders, Philadelphia, PA, pp 237-255, 1996.

35. Lockey, RF:

Insect and Arthropod Bites and Stings.

In: Current Practice of Medicine: Volume 2, Lieberman P. (Section Editor).

Bone RC (Series Editor).

Current Medicine, Inc., Philadelphia, PA., VII:10.1-10.10, 1996.

36. Szentivanyi A, Abarca CM, Brooks SM, Lockey RF, Prockop LD:

Some Evolutionary, Morphoregulatory, and Functional Aspects of the Immune-

Neuroendocrine Circuitry.

In: Immunopharmacology Reviews, Volume 2.

Hadden JW, Szentivanyi A (eds).

Plenum Publishing Corporation, New York, NY, pp 379-414, 1996.

37. Puerta L, Fernandez-Caldas E, Lockey RF:

Indoor Allergens: Detection and Environmental Control Measures.

In: Indoor Air Pollution and Health.

Bardana EJ, Jr. and Montanaro A (eds).

Marcel Dekker, Inc., New York, NY, pp 215-229, 1997.


Allergen Immunotherapy.

In: Allergic Diseases:Diagnosis and Treatment.

Lieberman P and Anderson JA (eds).

Humana Press, Totowa, New Jersey, pp 363-375, 1997.

39. Lockey RF:

Allergic Reactions to Insect Stings

In: Conn's Current Therapy, 1998 edition.

Robert E. Rakel, M.D. (ed).

W. B. Saunders Co., Philadelphia, PA, pp 767-770, 1998.

40. Nelson RP, Lockey RF:

Rhinitis and Sinusitis

In: Environmental and Occupational Medicine, 3rd edition.

William N. Rom, M.D., M.P.H. (ed)

Lippincott-Raven, Philadelphia, PA, pp 667-674, 1998.

41. Lockey RF, Nicoara-Kasti G:

Insect and Arthropod Bites and Stings

In: Current Practice of Medicine, Volume 1, Number 1

Fitzgerald FT (editor-in-chief)

Lieberman PL (section editor)

Current Medicine, Inc., Philadelphia, PA, pp 157-166, 1998.

6

42. Bukantz SC, Lockey RF, Kasti GL:

Adverse Effects and Fatalities Associated with Allergen Immunotherapy

In: Allergens and Allergen Immunotherapy, 2nd edition.

Richard F. Lockey, M.D. and Samuel C. Bukantz, M.D. (eds).

Marcel Dekker, Inc., New York, New York, pp 517-531, 1999.

43. Mohapatra SS, Lockey RF:

Weed Pollen Allergens




44. Fernandez-Caldas E, Puerta L, Lockey RF:

Mite Allergens





Selected Immunotherapy Patient Instructions and Consent Forms

In: Allergens and Allergen Immunotherapy, 2nd edition. Richard F. Lockey, M.D. and

Samuel C. Bukantz, M.D. (eds).


46. Lockey RF, Rosenbach KP, Nelson RP:

Insect Sting Hypersensitivity

In: Conn’s Current Therapy, 1999 edition.

Robert E. Rakel, M.D. (ed)

W. B. Saunders, Co., Philadelphia, PA, pp 786-791, 1999.

47. Fox RW, Lockey RW:

Allergen Immunotherapy In: An Expert Guide to Allergy

Slavin RG and Reisman RE (eds) American College of Physicians – American

Society of Internal Medicine, Philadelphia, PA, pp 211-226, 1999.

48. Bousquet J, Lockey RF, Malling HJ:

Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases

(WHO Position Paper, Executive Summary)In: Immunotherapy in Asthma

Bousquet J, Yssel H (eds) Marcel Dekker, Inc., New York, NY

Published, 1999.

49. Lockey RF, Nelson RP:

Insect and Arthropod Bites and Stings.

In: Current Practice of Medicine, Volume 2, Number 9

Gotto AM (editor-in-chief)

Lieberman PL,(section editor)

Current Practice, Inc., Philadelphia, PA, pp 1801-1810, 1999.


Allergens

In: Current Review of Allergic Diseases

Kaliner MA, M.D. (ed)

Current Medicine, Inc., Philadelphia, PA, pp 55-64, 2000.

7

51. Morena M, Lockey RF:

Insect Allergy

In: Allergy in Primary Care

Altman LC, Becker JW, Williams PV (eds)

W. B. Saunders, Philadelphia, PA, pp 293-304, 2000.


Allergen. In: Current Review of Allergic Diseases. (2nd edition) Ed. M Kaliner,

Current Medicine Inc, PA, pp-51-60, 2001.

53. Ramirez NC, Lockey RF:

Management of Acute Asthma in the Office Setting.

In: American College of Physicians (ACP) book, Asthma.

Slavin RG, Reisman RE (eds). American College of

Physicians, Philadelphia, PA, pp. 51-69, 2002

54. Codina R, Lockey RF:

Allergen Immunotherapy. In Atlas of Allergic Diseases, Lieberman PL, Blaiss MS

(eds). Current Medicine Inc., Philadelphia, Chapter 18, pp 161-7, 2002.

55. Lockey RF, Slater JE, Esch RE:

Preparation and Standardization of Allergen Extracts, In: Middleton’s Allergy

Principles & Practice. Adkinson NF, Yunginger JW, Busse WW, et al (eds).

Mosby, 1(6): Chapter 35, pp 573-584, 2003.

56. Lockey R, Reichmuth D:

Adverse Reaction to Skin Testing and Immunotherapy Using Venoms and Ant Whole

Body Vaccines. In Monograph on Insect Allergy 4th edition, Levine MI, Lockey RF.

(eds) Dave Lambert Asso., PA, Chap 11, pp.113-124, 2003.

.

57. Lockey R, Reichmuth D, Clinical Aspects of Ant Allergy. In Monograph on Insect

Allergy 4th ed. Levine MI, Lockey RF (eds) Dave Lambert Asso., PA,

Chap 13, pp.133-151, 2003.

58. Mohapatra SS, Lockey RF, Polo F:

Weed Pollen Allergens. In: Allergens and Allergen Immunotherapy, 3rd ed.

Lockey RF, Bukantz SC, Bousquet J (eds). Marcel Dekker, Inc., New York, NY.

Chap. 12, pp. 207-222, 2004.

59. Fernández-Caldas E, Puerta L, Caraballo L, Lockey RF:

Mite Allergens, In: Allergens and Allergen Immunotherapy, 3rd ed. Lockey RF,

Bukantz SC, Bousquet J (eds). Marcel Dekker, Inc., New York, NY.

Chap. 14, pp. 251-270, 2004.

60. Müller U, Golden DBK, DeMarco PJ, Lockey RF:

Immunotherapy for Hymenoptera Venom and Biting Insect Hypersensitivity. In:

Allergens and Allergen Immunotherapy, 3rd ed. Lockey RF, Bukantz SC,

Bousquet J (eds). Marcel Dekker, Inc., New York, NY,

Chap. 29, pp. 541-566, 2004.

8


Adverse Effects and Fatalities Associated with Subcutaneous Allergen

Immunotherapy. In: Allergens and Allergen Immunotherapy, 3rd ed. Lockey RF,

Bukantz SC, Bousquet J (eds). Marcel Dekker, Inc., New York, NY,

Chap. 39, pp. 711-727, 2004.

62. Cox L, Lockey RF:

Instructions and Consent Forms for Allergen Immunotherapy. In: Allergens and

Allergen Immunotherapy 3rd ed. Lockey RF, Bukantz SC, Bousquet J (eds).

Marcel Dekker, Inc., New York, NY. Chap. 41. pp.755-784, 2004.

63. Lockey RF, (contributor):

In Prevention of Allergy and Allergic Asthma, World Allergy Organization,

Johansson SGO, Haahtela T (eds.) Karger, Basel, Switzerland, Preventive

Measures: Section 1: Early Interventions, pp. 135-151, Allergy and Asthma

Education, pp. 163-183, 2004.

64. Codina R, Ramey J, Lockey R:

Allergen Immunotherapy. In: Atlas of Allergic Diseases, 2nd ed. Lieberman PL,

Blaiss MS (eds). Philadelphia, PA, pp. 164-174, 2005.


Insect Allergy. In: Atlas of Allergic Diseases, 2nd ed. Lieberman PL, Blaiss MS

(eds). Philadelphia, PA, pp. 220-226, 2005.


Allergen Immunotherapy. In: Allergic Diseases – Diagnosis and Treatment,

3rd ed. Lieberman P. Anderson JA (eds). Humana Press, Totowa, NJ. Chpt 26, pp

429-444, 2007.

66. Cole SL, Lockey RF:

Subcutaneous Allergen Immunotherapy and its Mechanisms. In: Recent Trends in

Aerobiology, Allergy and Immunology. Vijay HM, Kurup VP (eds). Research

Signpost, Kerala, India. Chpt 20, pp 391-403, 2008.

67. Slater JE, Esch RE, Lockey RF:

Preparation and Standardization of Allergen Extracts. In: Middleton’s Allergy:

Principles & Practice, 7th edition. Adkinson NF, Jr, Bochner BS, Busse WW, Holgate

ST, Lemanske RF, Jr, Simons FER (eds). Mosby, 1(7): Chapter 34,

pp 557-568, 2008.

68. Mohapatra SS, Lockey RF, Polo F:

Weed Pollen Allergens. In: Allergens and Allergen Immunotherapy, 4th ed. Lockey

RF, Ledford DK (eds). Informa Healthcare, New York, NY. Chap. 8, pp.127-139,

2008.

69. Fernández-Caldas, E, Puerta L, Caraballo L, Lockey RF:

Mite Allergens. In: Allergens and Allergen Immunotherapy, 4th ed. Lockey RF,

Ledford DK (eds). Informa Healthcare, New York, NY. Chap. 10, pp.161-182, 2008.

70. Müller U, Golden DBK, Lockey RF, Shin B:

Immunotherapy for Hymenoptera Venom Hypersensitivity. In: Allergens and

Allergen Immunotherapy, 4th ed. Lockey RF, Ledford DK (eds). Informa Healthcare,

New York, NY. Chap. 24, pp.377-392, 2008.

9

71. Bukantz SC, Bagg AS, Lockey RF:

Adverse Effects and Fatalities Associated with Subcutaneous Allergen

Immunotherapy. In: Allergens and Allergen Immunotherapy, 4th ed. Lockey RF,

Ledford DK (eds). Informa Healthcare, New York, NY. Chap. 29, pp.455-468, 2008.


Instructions and Consent Forms for Subcutaneous Allergen Immunotherapy. In:

Allergens and Allergen Immunotherapy, 4th ed. Lockey RF, Ledford DK (eds).

Informa Healthcare, New York, NY. Chap. 32, pp.499-525, 2008.

73. Kemp SF, Lockey RF:

Mechanisms of Anaphylaxis. In: Allergy Frontiers: Clinical Manifestations, Volume

3. Pawankar R, Holgate ST, Rosenwasser LJ (eds). Springer, Japan. Chapter 23, pp.

367-377, 2009.

74. Kemp SF, Lockey RF:

Pathophysiology and organ damage in anaphylaxis. In: Anaphylaxis and

Hypersensitivity Reactions, 1st edition. Castells MC (ed). Springer, New York, NY.

Chapter 3, pp 33 - 46, 2011.

75. Lockey RF, Kemp SF, Simons FER, Lieberman PL,Sheikh A:

The Burden of Allergic Diseases: Anaphylaxis. In: WAO White Book on Allergy.

Pawankar R, Canonica GW, Holgate ST, Lockey RF (eds). World Allergy

Organization, Milwaukee, Wisconsin. Chapter 2, pp 43 – 47, 2011.

76. Jutel M, Fukuda T, Frew A, Bonadonna P, Lockey RF:

Burden of Allergic Diseases: Insect Allergy. In: WAO White Book on Allergy.

Pawankar R, Canonica GW, Holgate ST, Lockey RF (eds). World Allergy

Organization, Milwaukee, Wisconsin. Chapter 2, pp 62– 65, 2011.

77. Fitzhugh DJ, Lockey RF:

History of Immunotherapy: The First 100 Years. In: Immunology and Allergy

Clinics of North America. Cox L (Guest ed). Alam R (Consulting ed). W. B.

Saunders, Philadelphia, PA. Vol 31 (2), Chapter 1, pp. 149 – 157, 2011.

78. Lockey RF:

Immunotherapy for Venom Allergy Comes of Age. In: Landmark Papers in Allergy.

Sheikh A, Platts-Mills T, Worth A (eds). Oxford University Press, Oxford, UK.

Chapter 48, pp 159-161, 2013.

79. Lockey RF:

Gastroesophageal Reflux Disease and Asthma. In: Global Atlas of Asthma. Akdis

CA, Agache I (eds). European Academy of Allergy and Clinical Immunology

(EAACI), Section B, Chapter 5, pp. 95-99, 2013.

80. Pesek R, Lockey RF:

Diagnosis and Management of Allergy to Hymenoptera (and other insects) Stings in

Adolescents and Children. In: Clinical Decision Support: Pediatrics. McMillan JM,

Barrett DJ, Boney CM, Jones MD (eds). Decision Support in Medicine, LLC.

Wilmington, DE, 2013.

10

81. Fernández-Caldas E, Puerta L, Caraballo L, Lockey RF:

Mite Allergens. In: Allergens and Allergen Immunotherapy: Subcutaneous,

Sublingual and Oral, 5th ed. Lockey RF, Ledford DK (eds). CRC Press/Taylor

& Francis Group, New York, NY, pp 181-201, 2014.

82. Müller U, Golden DBK, Lockey RF, Shin B:

Immunotherapy for Hymenoptera Venom Hypersensitivity. In: Allergens and

Allergen Immunotherapy: Subcutaneous, Sublingual and Oral,, 5th ed.

Lockey RF, Ledford DK (eds). CRC Press/Taylor & Francis Group, New

York, NY, pp 401-15, 2014.

83. Bagg AS, Lockey RF:

Adverse Effects and Fatalities Associated with Allergen Skin Testing and

Subcutaneous Allergen Immunotherapy. In: Allergens and Allergen

Immunotherapy: Subcutaneous, Sublingual and Oral, 5th ed. Lockey RF,

Ledford DK (eds). CRC Press/Taylor & Francis Group, New York, NY, pp

447-59, 2014.


Instruction and Consent Forms for Subcutaneous Allergen Immunotherapy.

In: Allergens and Allergen Immunotherapy: Subcutaneous, Sublingual and

Oral, 5th ed. Lockey RF, Ledford DK (eds). CRC Press/Taylor & Francis

Group, New York, NY, pp 497-512, 2014.

85. Teng MN, Lockey RF:

Innate Immune Response in Allergy. In: Global Atlas of Allergy,

Akdis CA, Agache I (eds). Published by the European Academy of Allergy and

Clinical Immunology (EAACI), pp 43 – 44, 2014.

86. Glaum MC, Lockey RF:

Allergen Specific Immunotherapy and Systemic Reactions. In: Anaphylaxis.:

Principles and Practice. Mamidipudi KT (ed). Nova Science Publishers, Inc.,

New York, 2013.

ABSTRACTS:

(* presented)

*1. Sanbar SF, Mitchell SA, Lockey RF, Vleck EA, Green JA:

Metabolic Effects of Hypotension Induced by Hemorrhage and

by Hypotensive Drugs.

Clin Res, Vol XV, 3:410, 1967.

*2. Lockey RF, Cortes F:

Cardiac Hemodynamics and Pulmonary Function in Patients With

Status asthmaticus.

Clin Res, Vol XVII, 2:251, 1969.

11

*3. Zeiss CR, Lockey RF:

An Extended Refractory Period to Adverse Effects of Aspirin

in a Patient With the ASA-Triad.

J Allergy Clin Immunol 53(2):113, 1974.

*4. Lockey RF:

Systemic Reactions to Stinging Ants.

Clinical Medicine p 30, June 1975.

*5. Bukantz SC, Lockey RF, Baird I:

Diverse Reactivity of Cat Dander Extracts.

J Allergy Clin Immunol 57:238, 1976.

*6. Parrino J, Kandawalla N, Lockey RF:

Treatment of the Local Skin Response to Imported Fire Ant Sting.


*7. Phillips JW, Goldman AL, Lockey RF:

Bahia Grass Pollen - an Important Aeroallergen.


*8. Bukantz SC, Lockey RF, Baird I:

Studies With Cat Saliva Allergen.


*9. Adelman HM, Lowenstein MB, Trunnell T, Lockey RF:

Urticaria and Eosinophilic Fascitis.


*10. Lockey RF, Baird I, Myers C, Mack G, Turkeltaub P, et al:

Hymenoptera Venom Study. Committee on Insects.

Allergy Clin Immunol, Supplement to Vol 67:86, 1981.

*11. Lockey RF, Fox RW, Bukantz SC:

Neurologic Sequelae (NS) Following the Imported Fire Ant (IFA) Sting.

J Allergy Clin Immunol, Supplement to Vol 67:31, 1981.

*12 Asai S, Krzanowski J, Anderson W, Martin D, Lockey R, Bukantz S, Szentivanyi A:

Effects of the Toxin of Red Tide, Ptychodiscus revis (PB),

on Canine Tracheal Smooth Muscle.

J Allergy Clin Immunol, Supplement to Vol 67:20, 1981.

*13. Krzanowski J, Asai S, Anderson W, Martin D, Lockey R, Bukantz S, Szentivanyi A:

Contractile Effects of Ptychodiscus brevis Toxin on Canine

Airways Smooth Muscle.

Federation of American Societies for Experimental Biology,

abstract of papers 1-3266: p 721, 1981.

*14. Fox R, Bukantz S, Millns J, Espinoza L, Lockey R:

Immunologic aspects of Fixed Drug Eruptions.

Association of Clinical Scientists,

Abstracts p. 7, May 7-10, 1981.

12

*15. Fox R, Bukantz S, Vogel F, Millns J, Espinoza L, Lockey R:

Immunologic Evaluation of a fixed Drug Eruption to

Pseudoephedrine (PS).

Annals of Allergy 47:120, 1981.

*16. Fox R, Bukantz S, Samaan S, Lockey R:

Theo-Dur Bioavailability in Geriatric age Group.


*17. Stablein JJ, Binford LR, Bukantz SC, Lockey RF:

Melaleuca (M) Tree and Respiratory Disease.


*18. Krzanowski JJ, Asai S, Martin DF, Lockey RF, Bukantz SC, Szentivanyi A:

Effects of the Imported Fire Ant (Solenopsis invicta) Venom

on Canine Tracheal Smooth Muscle Contraction Induced by Axonal

Sodium Channel Stimulators (Ptychodiscus brevis Toxin, Veratridine and Scorpion

Toxin).

J Allergy Clin Immunol, Supplement to Vol 69(1):119, 1982.

*19. Asai S, Krzanowski JJ, Martin DF, Lockey RF, Bukantz SC, Szentivanyi A:

Ptychodiscus brevis Toxin (PBTX) Stimulates a New Receptor Site in Activating

Parasympathetic Nerve Axonal Voltage-sensitive Sodium Channels.

J Allergy Clin Immunol, Supplement to Vol 69(1):120, 1982.

*20. Asai S, Krzanowski J, Martin D, Lockey R, Bukantz S, Szentivanyi A:

A new parasympathetic axonal sodium channel h gate stimulator,

Ptychodiscus brevis toxin (PBTX).

XI International Congress of Allergology and Clinical Immunology,

Abstract 42, 1982.

*21. Bukantz S, Samaan S, Fox R, Lockey R:

Pharmacokinetics of theophylline in geriatrics.

XI International Congress of Allergology and Clinical Immunology,

Abstract 320P, 1982.

*22. Lockey R, Peppe B, Baird I, Turkeltaub P:

Hymenoptera venom study (HVS) safety.

J Allergy Clin Immunol, Supplement, 71:141, 1983.

*23. Peppe BC, Lockey RF, Madden J, Baird I, Turkeltaub P:

Hymenoptera venom study (HVS), treatment results.


*24. Louie SJ, Krzanowski JJ, Bukantz SC, Lockey RF:

Ergonovine effects on airway smooth muscle contractile responses.


*25. Johansson SGO, Lockey RF:

RAST studies of allergy to imported fire ant, (IFA),

(Solenopsis invicta).


13

*26. Bucholtz G, Lockey R, Binford L, Serbousek D:

Allergenicity of the bald cypress tree (Taxodium distichum).


*27. Hensel AE, Lockey RF:

Death from imported fire ant, Solenopsis invicta.

Ann Allergy 50:359-60, 1983.

*28. Wells JH, Lerner MR, Martin DF, Strecker RA, Lockey RF:

The effect of respiratory exposure to red tide toxin on airway

resistance in conscious guinea pigs.

J Allergy Clin Immunol 73(1):1984.

*29. Samaan S, Fox RW, Bukantz SC, Lockey RF:

Comparison of theophylline (T) disposition in elderly smokers

and non-smokers.


*30. Fox R, Samaan S, Bukantz S, Lockey R:

Comparison of diurnal and nocturnal theophylline disposition.


*31. Lockey R, Fox R, Millns J, Espinoza C, Bukantz S:

Probable immunologic role of Langerhan's cells in fixed drug

eruption (FDE) to pseudoephedrine (PS).


*32. Fox RW, Samaan S, Bukantz S, Lockey R:

Comparison of diurnal and nocturnal theophylline disposition.

First International Montreux Conference on Chronopharmacology,

Montreux, Switzerland, March 26-30, 1984.

*33. Krzanowski J, Sakamoto Y, Duncan R, Martin D, Lockey R, Hunter K:

The Mechanism of Ptychodiscus brevis toxin (PBTX).

Pharmacologist 26:175, 1984.

*34. Sakamoto Y, Krzanowski J, Lockey R, Polson J, Szentivanyi A:

The mechanism of ergonovine-induced airway smooth muscle contraction.

Pharmacologist 26:152, 1984.

*35. Ledford DK, Lockey RF, Serbousek D, Park J, TeStrake D:

Studies on airborne pollens and fungi during grass mowing.

Southeastern Branch, American Society for Microbiology,

Clearwater Beach, Florida, October 25-27, 1984.

*36. Ledford DK, Overman MD, Gonzalvo A, Cali A, Mester SW, Lockey RF:

Microsporidiosis myositis in the acquired immune deficiency

syndrome.

American College of Allergists, Bal Harbour, Florida,

February 2-6, 1985.

*37. Lockey R, Benedict L, Turkeltaub P:

Fatalities (F) from immunotherapy (IT) and skin testing (ST).

J Allergy Clin Immunol, Supplement, 75(1):166, 1985.

14

*38. Bucholtz G, Hensel A, Lockey R, Serbousek D, Ledford D:

Allergenicity of the Australian pine pollen (Casuarinaequisetifolia).

J Allergy Clin Immunol, Supplement, 75(1):119,1985.

*39. Nordvall SL, Johansson SGO, Ledford D, Lockey R:

Allergens of imported fire ant (IFA), Solenopsis Invicta.


*40. Krzanowski J, Sakamoto Y, O'Connor C, Ledford D, Krzanowski J,

Lockey R:

The acute actions of gold salts on canine tracheobronchial smooth muscle.


*41. Sakamoto Y, Krzanowski J, Lockey R, Polson, Szentivanyi A:

The potential of ergonovine to precipitate bronchial asthmatic attacks via serotonin

receptors.


*42. Fox RW, Bukantz SC, Lockey RF:

Treatment of chronic idiopathic urticaria (CIU) with astemizole (A).


*43. Johansson SGO, Nordvall S, Ledford D, Lockey R:

Specific IgE and IgG responses to immunotherapy (IT) with imported fire ant whole

body extract (IFA-WBE) in IFA hypersensitivity (H).


*44. Ganguly R, Stablein J, Lockey RF, Baird I, Shamblin P, Serbousek D:

Salivary immunoglobulins in the aged.

Ann Allergy SS, 55(2):270,1985.

*45. Nelson RP, Bucholtz GA, Lockey RF, Baird-Warren I:

Cross-over study of cardiopulmonary effects of subcutaneous (SQ) albuterol (A) and

epinephrine (E) in reversible obstructive airway disease.

Ann Allergy 55(2):397,1985.

*46. Ganguly R, Lockey R:

Age interference of lymphokine production by lung derived lymphocytes.

Allerg Immunol 31:203,1985.

*47. Ledford D, Lockey R, Serbousek D, Park J, Te Strake D:

Studies on airborne fungal spores and pollens during grass mowing.

International Society of Human and Animal Mycoses.

Published abstract, p 27

Atlanta, GA,1985.

*48. Shimoda T, Krzanowski J, Lockey RF, Martin D, Duncan R:

The action of a natural environmental toxin, Ptychodiscus brevis,on lower airways.


*49. Ledford DK, Serbousek D, Lockey RF:

The effects of lawnmowing on airborne pollen and fungal spores.

J Allergy Clin Immunol, 77(1):243, 1986.

15

*50. Sher MR, Suchar DO, Lockey RF:

Anaphylactic shock induced by oral desensitization to trimethoprim/ sulfmethoxazole

(TMP-SMZ).


*51. Schwartz HL, Golden DBK, Lockey RF:

Venom immunotherapy (V.I.T.) and the pregnant woman with Hymenoptera allergy

(H.A.).


*52. Kemp JP, Meltzer EO, Orgel HA, Welch MJ, Lockey RF, Middleton E,

Spector SL, Perhach JL, Newton JL:

A dose-response study of the bronchodilator action of azelastine (AZEL) in asthma.


*53. Ganguly R, Stablein JJ, Lockey RF:

Salivary Opsonins in the aged.


54. Ganguly R, Stablein JJ, Lockey RF:

Microbicidal functions of oral secretions in the aged.

1986 ASM Annual Meeting, March 23-28, 1986, Washington, D.C.

*55. Robicsek S, Polson JB, Krzanowski J, Lockey RF, Szentivanyi A:

Separation of lymphocyte cyclic nucleotide phosphodiesterases by ion exchange high

pressure liquid chromatography. VIth International Conference on Cyclic

Nucleotides, Calcium and Protein Phosphorylation, September 2-7, 1986.

*56. Lockey RF, Nelson RP:

The use of glucocorticosteroids to treat asthma.

Southern Medical J 79:S2, 1986.

*57. Lockey RF, Minor M:

Sinusitis and asthma.

Southern Medical J 79:S2, 1986.

*58. Rastogi SC, Del Grosso A, Banov C, Brestel E, Findlay S,

Lockey R et al:

International collaborative evaluation of parallel-line skin test

assay (PLST) using 1.8 and 0.1 mg/ml histamine base.

J Allergy Clin Immunol 77(part 2):221, 1986.

*59. Shimoda T, Lockey R, Altman LC, Ayars GH, Krzanowski J:

Studies on the contractile effects of western red cedar extracts on canine tracheal

smooth muscle strips`.


*60. Robicsek S, Polson JB, Krzanowski JJ, Lockey RF, Szentivanyi A:

Study of human lymphocyte phosphodiesterase using high pressure liquid

chromatography.


*61. Fox RW, Fernandez-Caldas E, Bucholtz GA, Reed CE, Lockey RF:

Tampa Bay house dust mites (HDM) survey.

16


*62. Ledford DK, Bucholtz GA, Lockey RF:

Immunochemical characterization of Bahia grass (Paspalum notatum) pollen extract

(BPE) and cross reactivity with aqueous Bahia leaf extract (BLF).


*63. Nelson RP, Bucholtz GA, Minor MW, Ledford DK, Lockey RF:

Bayberry (Myrica cerifera) pollen as an aeroallergen.


*64. Bucholtz GA, Ledford DK, Lockey RF:

Immunochemical characterization of Australian pine (Casuarinaequisetifolia) pollen

extract.


*65. Krzanowski J, Shimoda T, Nelson R, Martin DF, Polson J,

Duncan R, Lockey R:

In vitro red tide toxin effects on human bronchial smooth muscle.


*66. Polson JB, Lockey RF, Bukantz SC, Lowitt S, Krzanowski J,

Szentivanyi A:

Effects of ketotifen on the responsiveness of human peripheral blood lymphocyte beta

adrenergic receptors.

The Pharmacologist 29:218, 1987.

*67. Krzanowski JJ, Duncan RA, Davis JS, Polson JB, Watanabe T,

Lockey RF, Szentivanyi A:

The formation of inositol 1,3,4,5, tetrakisphosphate (IP4) in isolated contracting

canine tracheal smooth muscle.

Xth International Congress of Pharmacology, Sydney, Australia, August, 1987.

*68. Fernandez-Caldas E, Fox R, Trudeau W, Swanson M, Reed C, Lockey R:

House dust mite allergy in Tampa, Florida.

42nd Annual Meeting, Southeastern Allergy Assoc., Inc. October 8-10, 1987,

Richmond, VA.

*69. Diaz J, Lockey R, Stablein J, Mines H:

Multiple imported fire ant (Solenopsis invicta) stings without systemic effects.

Annual Scientific Assembly of the Southern Medical Assoc.

November 1, 1987, San Antonio, TX.

*70. Berman A, Aguilar JL, Espinoza LR, Espinoza CG, Vasey FB,

Lockey RF, Germain B:

Identification of human immunodeficiency virus (HIV) antigens in synovial

membrane of patients with HIV-associated arthritis.

The 14th Southeastern Regional Meeting of the American

Rheumatism Association.

December 4, 1987, Nashville, TN.

17

*71. Krzanowski J, Watanabe T, Martin D, Polson J, Duncan R,

Lockey R:

Ptychodiscus brevis toxin (PBTX) induced alpha adrenergic contractile responses in

canine tracheal smooth muscle (CTSM).


*72. Watanabe T, Krzanowski J, Polson J, Duncan R, Lockey R:

Age related differences in development of histamine tachyphylaxis in canine airway

smooth muscle.


*73. Trudeau W, Fox R, Fernandez-Caldas E, Lockey R:

Flea, an indoor allergen.


*74. Fernandez-Caldas E, Fox R, Trudeau W, Lockey R:

Allergenicity of the mite, Blomia tropicalis.


*75. Fox R, Lockey R:

Treatment of severe, chronic urticaria (SCU) with dapsone.


*76. Banerji D, Fox R, Seleznick M, Lockey R:

A controlled trial of oral nalmefene (N) in chronic urticaria (CU) and atopic dermatitis

(AD).


*77. Wright D, Nelson R, Ledford D, Lockey R:

Serum IgE and human immunodeficiency virus (HIV).


*78. Lind P, Schou C, Lowenstein H, Lockey R:

Characterization of cockroach extracts and purification of a cross-reacting, acidic

allergen.


*79. Polson J, Lockey R, Bukantz S, Lowitt S, Krzanowski J, Szentivanyi A:

Responsiveness of lymphocyte beta adrenergic receptors in patients treated with

ketotifen.

Clinical Pharmacology and Therapeutics 43:137, 1988.

*80. Robicsek S, Polson JB, Krzanowski J, Lockey RF, Szentivanyi A:

High pressure liquid chromatography of human T-lymphocyte phosphodiesterases.

Clinical Pharmacology and Therapeutics 43:167, 1988.

*81. Berman A, Espinoza L, Diaz J, Rolando T, Vasey F, Lockey R,

Germain B:

The rheumatological manifestations of human immunodeficiency syndrome (HIV)

infection.

Arthritis and Rheumatism 31:R27, 1988.

18

*82. Berman A, Espinoza L, Blitz B, Rolando T, Nelson R, Lockey R,

Germain B:

Autoantibodies in human immunodeficiency syndrome (HIV) infection with

musculoskeletal involvement.

Arthritis and Rheumatism 31:R44, 1988.

*83. Minor MW, Nelson RP, Wright DN, Lockey RF:

Adult immunization in human immunodeficiency virus (HIV) infection.

XIII International Congress of Allergology and Clinical Immunology

Oct. 16-21, 1988, Montreux, Switzerland.

84. Schou C, Lind P, Fernandez-Caldas E, Lowenstein H, Lockey RF:

Demonstration of cockroach allergen in house dust samples.

European Academy of Allergology and Clinical Immunology Annual Meeting,

Copenhagen, Denmark, June 18-22, 1988.

*85. Fernandez-Caldas E, Trudeau W, Sanchez-Medina M, Cuadros G, Arlian LG,

Vyszenski-Moher DL, Arruda LK, Chapman M, Lockey RF:

Demonstration of allergenic components in extracts of the mite Blomia tropicalis.

J Allergy Clin Immunol 83(1): 292, 1989.

*86. Wright DN, Ledford DK, Lockey RF:

Systemic allergic reaction to the Tine Test purified protein derivative (PPD).


*87. Bucholtz GA, Trudeau W, Fernandez-Caldas E, Jelks M, Wunderlin R, Lockey RF:

Comparison of Australian pine species, Casuarina equisetifolia and Casuarina

cunninghamiana.


*88. Aronoff D, Ledford DK, Schou C, Fernandez-Caldas E, Trudeau W,

Lockey RF:

House dust mite and cockroach allergen concentrations in daycare centers.


89. Trudeau W, Fernandez-Caldas E, Fox R, Lockey R:

Mite aeroallergen concentrations before, during and after vacuum cleaning.


*90. Fox R, Lockey R, Altman L, Lieberman P, Wasserman S, Whitcomb N,

Altman R, Love S, Samuels L:

Cetirizine in the treatment of seasonal rhinitis.


*91. Krzanowski J, Watanabe T, Lockey R, Polson J:

Enhanced contractile responses of canine tracheal smooth muscle (CTSM).

J Allergy Clin Immunology 83(1):182, 1989.

*92. Diaz JD, Nelson RP, Lockey RF, Good RA, Day NK:

Systemic lupus erythematosis (SLE) presenting as human immuno-deficiency virus

(HIV) infection.


19

93, Nelson RP, Wright DN, Russell DH, Ledford DK, Lockey RF, Good RA:

Serum prolactin levels in patients with human immunodeficiency (HIV) infection.

Fifth International Conference on AIDS, June 4-9, 1989,

Montreal, Canada.

*94. Brooks SM, Fox RW, Spaul W, Fernandez-Caldas E, Lockey RF:

Host factors for developing symptoms from indoor air pollution.

AM Rev Resp Dis 139(4):A1-A652, 1989.

*95. Ganguly R, Chmel H, Lockey RF, Park J:

Vitamin C mediated enhancement of secretory antibody response to viral antigens.

30th Annual Meeting of the American College of Nutrition,

Sept. 25-26, 1989, Norfolk, VA.

*96. Schou C, Fernandez-Caldas E, Lockey RF, Lowenstein H:

Assay for cockroach allergen exposure.

Allergologie, 1989.

*97. Sanchez M, Fernandez-Caldas E, Trudeau W, Cuadros G, Lockey RF:

Prevalence of specific IgE to 5 different mite species in Bogota, Colombia.


*98. Fernandez-Caldas E, Trudeau W, Fox RW, Bucholtz GA, Lockey RF:

Comparison of mite specific IgE and total IgE levels in rhinitis and asthma patients.


*99. Trudeau W, Fernandez-Caldas E, May J, Pratt D, Lockey R:

Allergenicity of the mite Chortoglyphus arcuatus.


*100. Lockey RF, Turkeltaub PC, Hubbard JM, Olive ES, Bukantz SC:

The Hymenoptera Venom Study (HVS), V, 1979-1982, Efficacy.


*101. Silton RP, Fernandez-Caldas E, Trudeau WL, Lockey RF:

Allergenicity of the mite, Aleuroglyphus ovatus.


*102. Russell DW, Fernandez-Caldas E, Trudeau WL, Swanson MC, Seleznick MJ,Lockey RF:

Caffeine, a natural acaricide?


*103. Fox RW, Lockey RF, Altenburger K, Cohan R, Klotz S:

Clinical evaluation of the safety and efficacy of astemizole/ pseudoephedrine

combination in the treatment of fall hayfever.


*104. Wright DN, Trudeau WL, Fernandez-Caldas E, Bucholtz GA, Jelks ML, Lockey RF:

Cross-reactivity between white oak (Quercus alba) and laurel oak (Quercus laurifolia).


*105. Calderon EG, Fernandez-Caldas E, Lockey RF, Coffey RG:

Second messenger enzyme abnormalities in leukocytes of atopic subjects.

20


*106. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TAE:

Fatalities (F) from Immunotherapy (IT) and skin testing (ST).


*107. Codina R, Fernandez-Caldas E, Trudeau WL, Rodrigo MJ, Pena M,

Cadahia A, Botey J, Lockey RF:

Prevalence of specific IgE to storage mites in a population allergic to house dust mites

from the Barcelona area.

Clin Exp Allergy 20(1):117, 1990.

*108. Codina R, Fernandez-Caldas E, Trudeau WL, Rodrigo MJ, Morell F,

Lockey RF:

Study of the possible aetiologic role of mites in asthma caused by soybean dust

inhalation.

Clin Exp Allergy 20(1):117, 1990.

109. Codina R, Fernandez-Caldas E, Trudeau WL, Rodrigo MJ, Morell F,

Lockey RF:

Estudi de l'eventual paper dels acars en l'etiologia de les epidemies d'asma per

inhalacio de pols de soja.

Ann Med (Barc) Vol. LXXVI, No. 3, p 30, March 1990.

110. Bucholtz GA, Russell DW, Nelson RP, Fernandez-Caldas E,

Lockey RF:

Aerosolized pentamidine prophylaxis against pneumocystis carinii pneumonia using a

lower dose and a more efficient nebulizer system.

Amer Rev Resp Dis 141:A269, 1990.

*111. Morell F, Fernandez-Caldas E, Rodrigo MJ, Codina R, Lockey RF:

Estudio del posible role etiologico de los acaros de productos almacenados en las

epidemias de asma causadas por la inhalacion de soja en Barcelona.

Annual meeting of la Sociedad Espanola de Pneumologia. July, 1990, Tenerife,

Spain.

*112. Lockey RF et al:

Hymenoptera venom study: skin test results and safety of venom skin testing.

Allergy Digest 3:14-15, 1991.

*113. Askar ME, Wright DN, Ledford DK, Krzanowski JJ, Shabayek HA, Lockey RF:

The effect of heat on murine keratinocyte-derived relaxing factor.


*114. Dajani N, Wright DN, Ledford DK, Askar ME, Anile P, Krzanowski JJ, Lockey RF:

The effects of cultured murine keratinocyte suspension supernatant (MKSS) on canine

bronchial smooth muscle (BSM).


*115. Trudeau WL, Fernandez-Caldas E, Ledford DK, Bucholtz GA, Lockey RF:

Immunochemical analysis of bahia grass (Paspalum notatum) pollen extract.


21

*116. Garcia-Ibanez R, Fernandez-Caldas E, Garcia-Ramos E, Arango L,

Lockey RF:

Aeroallergen sensitivity in high altitude Guatemala City.

J Clin Allergy Immunol 87(1):293, 1991.

*117. Fernandez-Caldas E, Trudeau WL, Garcia-Ramos E, van Hage-Hamsten M, Johansson SGO,

Lockey RF:

Sensitization to house dust and storage mites in urban dwellers.


*118. Sanchez M, Fernandez-Caldas E, Swanson M, Schou C, Trudeau WL, Garcia-Ramos E,

Lockey RF:

Group I mite allergen concentrations in Bogota, Colombia.


*119. Lockey RF, Garcia-Ramos E, Fernandez-Caldas E, Seleznick M:

Skin test reactivity and allergic respiratory symptoms in adolescents on a subtropical

island.


*120. Puerta L, Fernandez-Caldas E, Caraballo LR, Lockey RF:

Cross-reactivity among Blomia tropicalis, Lepidoglyphus destructor and

Dermatophagoides farinae.


*121. Nelson R, Price L, Russell D, Halsey A, Resnick L, Day N, Lockey R, Good R:

HIV gene detection in infants and children.


*122. DiNicolo R, Nelson R, Fernandez-Caldas E, Trudeau W, Swanson M,

Bonini L, Perez A, Arthur P, Lockey R, Good R:

Allergen-specific IgE levels in children presenting to the emergency room with acute

asthma.


*123. Caraballo L, Puerta L, Fernandez-Caldas E, Lockey R:

Crossreactivity among Aleroglyphus ovatus, Chortoglyphus arcuatus and

Dermatophagoides.


*124. Hackney JF, Heim O, Schultze M, Wagner H, Zority J, Lockey RF,

Krzanowski J, Szentivanyi A:

Adrenergic mechanisms in the IL-3 and GM-CSF induced de novo synthesis or

histidine decarboxylase in hemopoietic progenitor cells.


*125. Robicsek S, Heim O., Reiner S., Hackney JF, Zority J, Lockey RF,

Szentivanyi A:

Characterization of the A549 B-adrenoceptor (BAR) regulating

protein components of lymphocyte conditioned medium(LCM) of IM9 cells.


22

*126. Szentivanyi A, Schultze M, Heim O, Reiner S, Robicsek S, Zority J,

Hackney JF, Lockey RF:

Resolution of the B-adrenoceptor (BAR) regulating activity in A549 lung cells of

lymphocyte conditioned medium (LCM) derived from cultured IM9 cells with DEAE

ion exchange HPLC.


*127. Van As A, Bronsky E, Chervinsky P, Dockhorn R, Furukawa C, Grossman J, Lockey R,

Lumry W, Meltzer E, Nathan R, Seltzer J, van Bavel J, Rogenes P:

Fluticasone propionate once daily is as effective as beclomethasone dipropionate

twice daily for perennial allergic rhinitis.


*128. Askar ME, Ledford DK, Krzanowski JJ, Lockey RF:

The effect of alpha-glucosidase and N-methyl arginine in murine keratinocyte

suspension supernatant-derived relaxing factor.

Southeastern Allergy Association, 10/4/91.

*129. Nelson RP, Price L, DiNicolo R, Halsey A, Day NK, Lockey RF,

Good RA:

Polymerase chain reaction (PCR) sensitivity and specificity

in infants and children.

Poster presentation, 7th International Conference on AIDS, Florence, Italy, June 16-

21, 1991, Abstract Book 1:126, 1991.

*130. Garcia-Ramos E, Fernandez-Caldas E, Seleznick MJ, Lockey RF:

Correlation between a family history of asthma and signs of atopy in adolescents on a

subtropical island.

Interasma 91, Funchal, Madeira, Portugal, May, 1991

*131. Nelson RP, Fernandez-Caldas E, Di Nicolo R, Trudeau WL, Bonini LV, Lockey RF, Good

RA:

Mite-specific IgE in pediatric acute asthma.

XIV International Congress of Allergology and Clinical Immunology. Kyoto, Japan,

October 13-18, 1991. Allergy & Clinical Immunology News, Supplement No. I,

1991, pg. 179.

*132. Calderon EG, Heim O, Szentivanyi A, Schultze P, Wagner H, Zority J, Lockey RF, Dwornik

JJ, Robicsek S:

Adrenergic and histamine receptor concentrations in bone marrow cells (BMC).


*133. Szentivanyi A, Calderon EG, Heim O, Schultze P, Wagner H, Zority J.

Lockey RF, Dwornik JJ, Robicsek S:

Cell- and species-specific dissociation in the B-adrenoceptor

(BAR) upregulating effects of IL-1a derived from lymphocyte conditioned medium

and cortisol.


*134. Askar ME, Ledford DK, Krzanowki JJ, Lockey RF:

Characterization of the molecular weight of the murine keratinocyte

suspension supernatant (MKSS) derived bronchial smooth muscle (BSM) relaxing

factor.

23


*135. Robicsek S, Szentivanyi A, Calderon EG, Heim O, Schultze P, Wagner H,

Lockey RF, Dwornik JJ:

Concentrated IL-1a derived from human T-lymphocytes binds to a specific single

class surface receptor on human bronchial epithelial cells and induces the reduction

of B-adrenoceptor(BAR) mRNA via an associated or separate receptor-linked

signaling pathway.


*136. Reid MJ, Lockey RF, Turkeltaub P, Platss-Mills TAE, Lehrer SB:

Fatalities from immunotherapy(IT) 1990-91.


*137. Dwornik JJ, Szentivanyi A, Heim O, Schultze P, Wagner H, Zority J,

Calderon EG, Lockey RF:

IL-1a may replace requirement for adrenergic input in the sensitization of bone

marrow hemopoietic progenitor cells (BMC) to the IL-3 and GM-CSF induced de

novo synthesis of histidine decarboxylase (HDC).


*138. Trudeau W, Fernandez-Caldas E, Lee D, Lockey RF:

Molecular weights and isoelectric points of Blomia tropicalis allergens.


*139. Edwards T, Trudeau W, Fernandez-Caldas E, Lee D, Seleznick MJ,

Lockey RF:

Proteinases in storage mite extracts.

J Allergy Clin Immunol 89(1)148, 1992.

*140. Jacinto CM, Fernandez-Caldas E, Trudeau WL, Lockey RF:

Skin test reactivity to Blomia tropicalis in subjects with asthma and/or rhinitis.


*141. Szentivanyi J, Heim O, Schultze P, Wagner H, Calderon EG, Lockey RF, Robicsek S,

Szentivanyi A:

Similarities and differences in patterns of B-adrenergic regulation by lymphocytic

proteins in respiratory and cutaneous atopy versus cystic fibrosis.


*142. Nelson RP, Price LJ, Halsey AB, Lockey RF, Good RA:

HIV gene detection in infants and children.


*143. Fernandez-Caldas E, Mercado R, Puerta L, Lockey RF, Carballo LR:

House dust mite sensitivity and mite fauna in the tropics.


*144. Puerta L, Fernandez-Caldas E, Mercado D, Lockey RF, Caraballo LR:

Blomia Tropicalis, Der p I and Der f I allergen levels in house dust samples in

Cartagena, Colombia.

J Allergy Clin Immunol 89(1): 316, 1992.

24

*145. Lowenstein H, Fernandez-Caldas E, Lockey RF, Matthiesen F:

Immunoelelectrophoretic analyses of the allergens in Paspalumnatatum (Bahia grass)

and Sorghum hapephense (Johnson grass) pollens.


*146. Szentivanyi A, Ali K, Calderon EG, Brooks SM, Coffey RG, Lockey RF:

The in vitro effect of immunoglobulin E (IgE) on cyclic AMP (cAMP) concentrations

in A549 human pulmonary epithelial cells with or without beta-adrenergic

stimulation.


*147. Predolini N, Sanchez G, Neffen H, Arlian LG, Fernandez-Caldas E,Trudeau WL, Lockey RF:

Sensitization to 7 domestic mites and mite allergen exposure in Argentina.


*148. Trudeau W, Codina Grau R, Rodrigo MJ, Fernandez-Caldas E,

Morell F, Lockey RF:

High molecular weight allergens in soybean hull extracts.

49th Annual Meeting of the American Academy of Allergy and Immunology,

Chicago, Illinois, March 1993.


*149. Ledford DK, Stewart GE, Diaz JD, Trudeau WL, Seleznick M, Lockey RF:

Comparison of oral pulse methotrexate with placebo in treatment

of severe glucocorticosteroid dependent asthma.


*150. Fernandez-Caldas E, Trudeau WL, Stewart GE, Swanson MC, Stanaland BE, Ledford DK,

Lockey RF:

Seasonal variations of Group I mite allergens in homes in Tampa, Florida.


*151. Stewart GE, Trudeau WL, Fernandez-Caldas E, Lockey RF:

Immunochemical characterization of Myrica cerifera (Bayberry) allergens.


*152. Sanchez-Medina M, Trudeau WL, Fernandez-Caldas E, Lockey RF:

Cutaneous sensitivity to inhalant allergens in Colombian Indian tribes.


*153. Baena-Cagnani CE, Fernandez-Caldas E, Patino C, Swanson MC,

Trudeau WL, Coello M, Lockey RF:

Comparisons of mite allergen levels in pillows and mattresses.


*154. Stanaland BE, Caplin JA, Hullet AC, Diaz JD, Fernandez-Caldas E, Lockey R:

The importance of sensitization to Blomia tropicalis in Corpus Christi, Texas.


*155. Fernandez AM, Patino CM, Salvucci KD, Fernandez-Caldas E,

Lockey RF, Baena-Cagnani C:

Prevalence of skin test sensitivity to 6 mite species in asthmatic adults.


25

*156. Puerta L, Mercado R, Martinez B, Fernandez-Caldas E, Arlian LG,

Lockey RF, Caraballo LR:

Emergency room asthma and domestic mites in Cartagena, Colombia.


*157. Askar ME, Ledford DK, Krzanowski JJ, Lockey RF:

Characterization of keratinocytes derived relaxing factor that modifies bronchial

smooth muscle contractility.


*158. Patino CM, Baena-Cagnani CE, Fernandez-Caldas E, Bustos GJ, Lockey RF:

Skin test sensitivity to 6 different mite species in asthmatic children (AC).


*159. Stein MR, Gonzalez GE, Stein AL, Fernandez-Caldas E, Lockey RF:

Dust mite allergy in south Florida.


160. Baena-Cagnani CE, Fernandez-Caldas, E, Patino CM, Lockey RF:

Mite species and allergens in dust samples from Cordoba, Argentina.

Interasma 93, XIV World Congress of Asthmology, Jerusalem,

Israel, October 24-29, 1993.

161. Ali K, Calderon EG, Brooks SM, Coffey RG, Lockey RF, Szentivanyi A:

The effect of IgE on beta-adrenergic responsiveness as measured by cyclic AMP

production of A549 Cells.

AAI/CIS 1993 Meeting.

J Immunol 150:345, 1993.

*162. Stanaland BE, Fernandez-Caldas E, Jacinto CM, Trudeau WL, Lockey RF:

Positive nasal challenges with Blomia tropicalis.


*163. Kemp SF, Fernandez-Cadas E, Trudeau WL, Lockey RF:

Mite aeroallergens are intermittently detectable in bedrooms and living rooms of

mite-allergic subjects.


*164. Stewart GE, Calderon E, Szentivanyi A, Lockey RF:

IgE decreases endothelin-1 (ET-1) production in A549 pulmonary epithelial cells.


*165. Andrade J, Fernandez-Caldas E, Trudeau WL, Ledford D, Souza-Lima E, Souza-Lima I,

Swanson MC, Lockey RF:

Serial determinations of Der pI and Der fI show predominance of one

Dermatophagoides species.


*166. Patino CM, Cuello MN, Trudeau BA, Fernandez-Caldas E, Puerta L, Lockey RF:

Seasonal variations of group I mite allergens in Argentina.


26

*167. Neffen HE, Jossen R, Araoz I, Sanchez-Guerra ME, Fernandez-Caldas E, Trudeau WL,

Lockey RF:

Socioeconomic status and sensitization to cockroach allergens in asthmatic children in

Santa Fe, Argentina.


*168. Fernandez AM, Patino CM, Fernandez-Caldas E, Puerta L, Lockey RF, Baena-Cagnani CE:

Skin test versus RAST to cockroach allergens.


*169. Puerta L, Fernandez-Caldas E, Mercado D, Lockey RF, Caraballo LR:

Seasonal variations of Blomia tropicalis, Der pI, Der fI, and Dermatophagoides spp.

allergens in the tropics.


*170. Naspitz CK, Rizzo MC, Fernandez-Caldas E, Sole D, Mimica I, Lockey RF:

Domestic endotoxin (ET) levels and bacterial exposure (BE) in houses from

asthmatics and controls, in Sao Paulo, Brazil.

1994 CIPP International Congress on Pediatric Pulmonology,

Nice, France, June 2-5, 1994.

*171. Puerta L, Fernandez-Caldas E, Lockey RF, Caraballo L:

Sensitization to aeroallergens as a risk factor for emergency room asthma.

The International Association of Allergology and Clinical Immunology and the

European Academy of Allergology and Clinical Immunology 1994 Meeting,

Stockholm, Sweden, June 26 - July 1, 1994.

*172. Fernandez-Caldas E, Naspitz CM, Rizzo CM, Lockey RF, Sole D, Mimica T:

Mite allergen and endotoxin levels in mattress and floor dust samples in Sao Paulo,

Brazil.




*173. Garcia-Ibanez R, Fernandez-Caldas E, Arango L, Lockey RF:

Aeroallergen sensitivity, mite fauna and mite allergen levels in Guatemala City.



Stockholm, Sweden, June 26 -July 1, 1994.

*174. Fernandez-Caldas E, Patino C, Cuello M, Lockey RF, Baena-Cagnani CE:

Mite allergen levels and mite fauna in pillows and mattresses in Cordoba, Argentina.




*175. Koutsonikolis A, Nelson RP, Fernandez-Caldas E, Brigino EM, Bradley WG, Lockey RF,

Good RA:

Total and specific IgE levels in children infected with human immunodeficiency

virus.


27

*176. Bodman S, Gross G, Lockey RF, Mansfield L, Prenner B:

Sodium cromoglycate 10 mg. four times daily: an effective treatment for adult

asthmatics.

Submitted to the 1994 European Respiratory Society.

*177. Patino CM, Fernandez-Caldas E, Yanez A, Neffen H, Arlian LG, Lockey RF, Baena-Cagnani

CE:

Argentinian Study and Asthma. I. Skin test sensitivity prevalence to D. pteronyssinus

and D. farinae. XV International Congress of the Allergology and Clinical

Immunology, Annual Meeting of the European Academy of Allergology and

Clinical Immunology. Allergy & Clinical Immunology News, Supplement No. 2, 99,

1994.

*178. Baena-Cagnani CE, Patino CM, Fernandez-Caldas E, Neffen H, Lisanti M, Arlian LG, Lockey

RF:

Argentininian Study and Asthma. II. Skin sensitivity to storage mites. XV

International Congress of Allergology and Clinical Immunology, Annual Meeting of

the European Academy of Allergology and Clinical Immunology.

Allergy & Clinical Immunology News, Supplement No. 2, 99, 1994.

179. Codina R, Morell F, Rodrigo MJ, Fernandez-Caldas E, Trudeau WL, Lockey RF:

Stability studies of soybean hull extracts.

University of South Florida Health Sciences Center. Faculty and Students Research

Day. Tampa, FL, October 1994.

*180. Kemp SF, Fernandez-Caldas E, Lockey RF, Stanaland BE, Arlian LG:

Skin test reactivity to Euroglyphus Maynei in Florida: A comparison with three other

house dust mite species.


*181. Puerta L, Caraballo LR, Fernandez-Caldas E, Avjioglu A, Marsh D, Lockey RF, Dao

ML:

Nucleotide sequence of a cDNA coding for a Blomia Tropicalis allergen.


182. Codina R, Morell F, Rodrigo MJ, Fernandez-Caldas E, Trudeau WL, Lockey RF:

Stability studies of soybean hull extracts.

51st Annual Meeting of the American Academy of Allergy and Clinical Immunology,

New York, February 1995.

J Allergy Clin Immunol 95(1):165, 1995

*183. Naspitz CK, Rizzo MC, Fernandez-Caldas E, Mimica I, Lockey RF:

The role of der p I intradomiciliar exposure on clinical severity of asthma, in Sao

Paulo, Brazil.


*184. Stanaland BE, Fernandez-Caldas E, Kemp SF, Brenner R, Lockey RF:

Nasal Provocation with cat flea, Ctenocephalides Felis, extract.


*185. Rizzo MC, Naspitz CK, Sole D, Fernandez-Caldas E, Mimica I, Lockey RF:

Clinical evaluation of asthmatic patients exposed to different levels of intradomiciliar

endotoxin (et), in Sao Paulo, Brazil.


28

*186. Lockey RF, Lavins BJ, Snader L:

Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) in patients with mild

to moderate asthma.


*187. Puerta L, Caraballo LR, Fernandez-Caldas E, Lockey RF, Dao M:

Expression of a Recombinant Blomia tropicalis Allergen.

XVI European Congress of Allergology and Clinical Immunology, European Journal

of Allergy and Clinical Immunology, Supplement No. 26, 50:134, 1995.

*188. Baena-Caganani C, Fernandez-Caldas E, Patino C, Cuello M, Arlian LG, Codina R,

Lockey RF:

Sensitization to Domestic Mites and Cross-Reactivity Studies in Argentina.



*189. Neffen H, Araoz I, Fernandez-Caldas E, Jossen R, Sarsotti P, Lauria M, Lockey RF:

Der p 1, Der f 1 Allergen Levels and Mold Counts in Homes of Asthmatic vs. Non-

Asthmatic Children.



190. Wood C, Aaronson D, Banov C, Chervinsky P, Dvorin D, Hampel F, Laforce C, Lockey RF,

Lumry W, Morgan W, Patel M, Ruoff G, Pearlman D, Storms W:

Double-Blind Placebo controlled Trial of Ipratropium Bromide (IB) Nasal Spray

0.06% and 0.12% in the Treatment of Allergic Perennial Rhinitis (APR)



*191. Codina R, Morell F, Rodrigo M, Fernandez-Caldas E, Trudeau W, Lockey RF:

Specific IgG to Soybean Hull Allergens in Soybean Asthma.

A Joint Conference sponsored by the American Academy of Allergy, Asthma and

Immunology and the American Thoracic Society, Chicago, IL, July 15-17, 1995.

Asthma '95 - Theory to Treatment (Abstract Book), page 8.

*192. Lockey RF, Lavins BJ, Snader L:

Thirteen weeks of treatment with zafirlukast (AccolateTM) in patients with mild to

moderate asthma.




*193. Kemp S, Fernandez-Caldas E, Lockey RF, Stanaland B, Arlian L:

Skin Test Reactivity to Euroglyphus Maynei in Florida: A Comparison with three

other house dust mite species.




*194. Kemp SF, Lockey RF, Wolf BL, Lieberman P:

Anaphylaxis: A review of 266 cases.

Allergy Proceedings, 16(6):311, Nov-Dec 1995.

29

*195. Hernandez LS, Fernandez-Caldas E, Lockey RF:

Nasal Provocation with Cockroach (CR) Extract.

American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting,

New Orleans, Louisiana, March 15-20, 1996.

J Allergy Clin Immunol 97(1):193, January 1996 .

196. Codina R, Lockey RF, Fernandez-Caldas E:

Specific Immunoglobulins to Soybean Hull Extracts in Soybean Asthma.

Health Sciences Research Day. University of South Florida, Tampa, Florida,

November 1995.

197. Codina R, Lockey RF, Fernandez-Caldas E:

Specific Immunoglobulins to Soybean Hull Allergens in Soybean Asthma.

American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting, New

Orleans, Louisiana, March 15-20, 1996.

J Allergy Clin Immunol 97(1):205, January 1996.

*198. Rodriguez A, Codina R, Fernandez-Caldas E, Leal FC, Lockey RF:

Partial Characterization of Fraxinus chinensis (Urapan) Allergens and cross-reactivity

among different Fraxinus species and Olea europea (Olive).




199. Wen Z, Codina R, Fernandez-Caldas E, Lockey RF, Bukantz SC:

Partial characterization of the silk allergens in mulberry silk extract.




*200. Rizzo MC, Naspitz CK, Fernandez-Caldas E. Mimica I, Lockey; RF, Sole D:

Relationship between intradomiciliar bacteria and fungi exposure and asthma.



J Allergy Clin Immunol 97(1):221, January 1996. .

*201. Lockey RF, Kemp SF, Fernandez-Caldas E:

Intranasal Provocation with Euroglyphus Maynei Extract.




202. Baena-Cagnani C, Fernandez-Caldas E, Arlian LG, Codina R, Cuello M, Patino C, Lockey

RF:

Sensitization to house dust mites in asthmatic children in Argentina and cross-

reactivity studies.




30

203. Codina R, Arlian LG, Fernandez-Caldas E, Patino C, Gurne SE, Lockey RF, Baena-Cagnani

CE:

Sensitization to house dust mites in asthmatic children in Argentina and cross-

reactivity studies.

XII Congreso Latinoamericano de Alergia e Inmunologia. New Orleans, Louisiana,

March 1996.

*204. Bukantz SC, Calderon E, Lockey RF:

Assay of ABO(H) Erythrocyte Antigen by Hemagglutination Inhibition of Murine

Monoclonal AntiA and AntiB Antibodies.

American Academy of Allergy, Asthma and Immunology 52nd Annual Meeting,

New Orleans, Louisiana, March 15-20, 1996.


*205. Kemp SF, Lockey RF:

Peanut Anaphylaxis: An Allergist-Immunologist's Personal Experience with Food

Cross-Contamination.




*206. Swank RL, Lockey RF, Hernandez LS, Coughlin JP:

Fire Ant Induced Skin Tissue Loss and Infection in a Nine Month Old Child.




207. Predolini N, Araoz J, Fernandez-Caldas E, Codina R, Lockey RF, Neffen H:

Variacion anual de los alergenos derivados de acaros (Grupo I) en Santa Fe, Argentina

(Seasonal variation of group 1 mite allergens). XII Congreso Latinoamericano de

Alergia e Inmunologia.

New Orleans, Louisiana, March 1996. South American meeting.

208. Nelson Jr. RP, Ledford DK, Zhou VA, Bergen-Losee L, Lockey RF:

Quantitative RNA Levels Before and After Influenza Immunization in HIV-Infected

Adults.

XIth International Conference on AIDS, Vancouver, British Columbia, July 7-12,

1996.

209. Chandra S, Lockey RF, Alidina LW, Beal D, Codina R, Gehring K:

Adverse health effects and elimination of dust mites in humid climate housing.

Proceedings of the 7th International Conference on Indoor Air Quality, (Indoor Air

'96), Nagoya, Japan, July 21-26, 1996, Vol 3: pp 433-438.

*210. Lockey RF, Codina R, Oehling AG, Ardusso LRF, Crisci CD, Bertoya NHI:

Prevalence of specific IgE and IgG4 in a rural population exposed to soybean dust in

Argentina.

American Academy of Allergy, Asthma and Immunology 53rd Annual Meeting, San

Francisco, California, February 21-26, 1997.

J Allergy Clin Immunol 99(1):S76, January 1997.

31

*211. Oehling AG, Codina R, Lockey RF:

Neoallergens as a possible cause of soybean-induced ashma.




*212. Fernandez-Caldas E, Trudeau WL, Ledford DK, Lockey RF:

How useful are room dehumidifiers to control mite allergen levels in bedroom carpets

in a subtropical city?




*213. Bukantz SC, Calderon E, Leparc G, Lockey RF:

Human Anti-A and Anti-B iso Antibodies may be produced by Genetically

Appropriate Responses to a Constant Endogenous Source of Blood Group Antigens in

Mucus.




*214. Ardusso LRF, Fernandez-Caldas E, Crisci CD, Ardusso DD, Lockey RF, Procopio N, Munoz

E, Galimany J, Marcipar A, Celentano O, Vacirca AI, Bertoya NHI:

Sensitization to Blomia tropicalis in a city of Argentina and its relationship with

different clinical and immunological parameters.




*215. Codina R, Lockey RF, Rama R:

Purification and sequencing of the main soybean hull allergen Gly m 2, responsible for

the Barcelona asthma outbreaks.




*216. Codina R, Lockey RF:

Aerobiologic Survey of the Tampa Bay Area, FL, USA, During 1996.

Aerobiology '97 - Pan American Aerobiology Association Annual Symposium,

Cambridge, Massachusetts, June 18-20, 1997.

*217. Chandra S, Parker D, Beal D, Lockey RF, Gehring K:

Eliminating dust mites in new homes through dehumidification.

Submitted for presentation, June 1997 ASHRAE meeting, Boston, MA.

*218. Bukantz SC, Calderon E, Leparc G, Zhang J, Lockey RF:

Human Anti-A and Anti-B Antibodies may be produced by genetically appropriate

responses to a constant endogenous source of blood group antigens in mucus. 13th

European Immunology Meeting, Amsterdam, Holland, June 22-25, 1997. 15th Aspen

Allergy Conference, Aspen, Colorado, July 22-25, 1997.

32

*219. Rosenbach KP, Ledford DK, Lockey RF:

Long-term use of Budesonide Turbuhaler on Steroid Dependent Asthmatics.




XVIth International Congress of Allergology and Clinical Immunology

Cancun, Mexico, October 19-24, 1997.

220. Chandra S, Beal D, Lockey RF, Codina R, Orr GW, Astry DW, Alidina LW:

Performance of Health Houses in Warm Humid Climates.

Proc. Healthy Buildings/IAQ '97 Conference, Washington, DC, September 27 -

October 2, 1997, Vol 3, pp 383-388.

*221. Rosenbach KP, Windom HH, Lockey RF:

A Simple Outpatient Aspirin Desensitization Protocol for ASA-Triad Subjects.



*222. Szentivanyi A, Heim O, Schultze M, Wagner H, Zority J, Lockey RF, Goldman A,

Krzanowski JJ, Polson J:

Effects of catecholamine and serotonin neurotoxins and exocitotoxic amino acids on

enhanced histamine production induced by rGM-CSF and/or rIL-3.



*223. Chandra S, Beal D, Codina R, Lockey RF:

Mites, mite allergens and interior environmental conditions in several homes in the

hot, humid southeastern United States.

Mites, Asthma & Domestic Design Workshop (MADD III), Wellington School of

Medicine, New Zealand, November 14 - 16, 1997.

*224. Behera AK, Kasti G, Kumar M, Matsuse H, Lockey RF, Mohapatra SS:

Molecular Alterations Caused by Respiratory Syncytial Virus (RSV) Invection in

Bronchial Epithelial Cells: An in vitro Model for Airway Inflammation.

American Academy of Allergy, Asthma and Immunology 54th Annual Meeting,

Washington, D.C., March 13-18, 1998

J Allergy Clin Immunol 101(1) Part 2:S17, January 1998.

*225. Reichart C, Codina R, Lockey RF, Montgomery T:

Evaluation of Four Fabric Pore Size Pillows (P) as Effective Filters of Dust Mite

Allergens.




*226. Kasti GL, Codina R, Ledford DK, Lockey RF:

Mite Contamination of Food Stuffs.




33

*227. Lockey RF, Codina R, Chandra S, Beal D:

Reduction of House Dust Mites in Homes Through Whole House

Dehumidification/Ventilation Systems (DVS).




*228. Thompson M, Shearer D, Lockey R, Fox R, Ledford D:

Systemic Reactions to Percutaneous (P) and Intradermal (ID) Skin Tests (ST).


Washington, D.C., March 13-18, 1998.


*229. Matsuse H, Behera AK, Kumar M, Lockey RF, Mohapatra SS:

In Vivo Cytokine Expression in Murine Lung and Spleen by Respiratory Syncytial

Virus and/or Dust Mite Allergens.




*230. Kumar M, Behera, AK, Matsuse H, Lockey RF, Mohapatra SS:

Development of BCG Based Allergy Vaccines: A Shuttle Plasmid Vector that Allows

Production and Secretion of Antigens.




*231. Rosenbach KP, Windom HH, Lockey RF:

A Simple Outpatient Aspirin Desensitization Protocol for ASA-Triad Subjects.




*232. Fox RW, Codina R, Lockey RF:

Possible Role of Molds as Secondary Etiologic Agents of the Asthma Epidemics in

Barcelona, Spain.




*233. Codina R, Lockey RF, Ardusso L:

Soybean Hull Allergens Induced by Heating and Storage American Academy of

Allergy, Asthma and Immunology 54th Annual Meeting, Washington, D.C., March

13-18, 1998.


*234. Ardusso LRF, Crisci CD, Codina R, Lockey RF, Galimany J, Marcipar A,

Massara A, Strass M, Bertoya NHI, Ardusso DD, Medina I, Trojavchich M,

Vinuesa M, Monje S:

Prevalence of sensitization to soybean hulls in subjects with asthma and/or rhinitis

from the south of Santa Fe and northeast of Buenos Aires.

XXII Annual Meeting of the Argentinian Allergy and Immunology Society:

Advances in Allergy, Asthma and Immunology, Buenos Aires, Argentina, August 15-

18, 1998.

34

*235. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS:

An IFN- Plasmid DNA Vaccine Protects BALB/c Mice Against Respiratory

Syncytial Virus Infection.

American Academy of Allergy Asthma and Immunology 55th Annual Meeting,

Orlando, Florida, February 26-March 3, 1999.


*236. Lockey RF, Codina R:

Mite Infestation in the Same Florida Home in Rooms with Or without Dogs.




*237. Matsuse H, Hu X, Lockey RF, Wolf S Mohapatra SS:

IL-12 Enhances the Shift from TH2- to TH1-like response in Mouse Model of Grass

Allergy.




*238. Ardusso L, Codina R, Crisci CD, Lockey RF, Bertoya N:

Prevalence of a Positive Skin test (ST) to Soybean Hull (SH) Allergens in Subjects

from Argentina with Asthma and/or Allergic Rhinitis (A-AR) Exposed to Soybean

Dust Inhalation (SDI)

February 26-March 3, 1999.


*239. Reichart CA, Lockey RF:

Treatment of Post Viral Cough with Inhaled Beclomethasone (IB).


Orlando, Florida, February 26-March 3, 1999.J Allergy Clin Immunol 103(1) Part

2:S136, January 1999.

*240. Codina R, Lockey RF, Ardusso L, Crisci CD, Bertoya N:

Prevalence of Specific IgE and IgG4 to Soybean Hull (SH) Allergens in Subjects from

Argentina with Asthma and/or Allergic Rhinitis (A-AR) Exposed to Soybean Dust

Inhalation (SDI). American Academy of Allergy Asthma and Immunology 55th

Annual Meeting, Orlando, Florida, February 26-March 3, 1999.


*241. Matsuse H, Behera AK, Kumar M, Lockey RF, Mohapatra SS:

The Mechanism of Synergy between Allergic Sensitization and RSV Infection.

American Thoracic Society, 1999 International Conference, San Diego, California,

April 23-28, 1999.

American Journal of Respiratory and Critical Care Medicine, 159(3):A104, March

1999.

*242. Theodoropoulos DS, Lockey RF, Rodriguez JA, Boyce HW, Jr., Johnson M, Ledford DK:

Upper Respiratory Symptoms in Patients with Gastroesophageal Reflux.


April 23-28, 1999.

American Journal of Respiratory and Critical Care Medicine,

159(3):A123, March 1999.

35

*243. Reichart CA, Rosenbach KP, Windom H, Lockey RF:

Outpatient Aspirin Desensitization Protocol for ASA-Triad Subjects.

American Thoracic Society, 1999 International Conference, San

Diego, California, April 23-28, 1999.

American Journal of Respiratory and Critical Care Medicine,

159(3):A125, March 1999.

*244. Behera AK, Matsuse H, Kumar M, Rabb H, Lockey RF, Mohapatra SS:

Role of Intercellular Adhesion Molecule-1 in Initiation of Respiratory Syncytial Virus

Infection.


April 23-28, 1999.

American Journal of Respiratory and Critical Care Medicine, 159(3):A308, March

1999.

*245. Kuderer NM, San Juan H, Kong X, Esch R, Lockey RF, Mohapatra SS:

Allergen-Induced Production of Interleukin-8 by Human Airway Epithelial Cells

Involves

Activation of p44/42 MAP Kinase.

American Thoracic Society, ATS 2000*TORONTO, the 96th International

Conference, Toronto,

Ontario, Canada, May 10, 2000.

*246. Tan BM, Fox RW, Lockey RF, Good RA:

Imported Fire Ant (IFA) Anaphylaxis Associated Seizure – A Case Report.

Amrican Academy of Allergy Asthma and Immunology 56th Annual Meeting, San

Diego, California, March 3 - March 8, 2000.


*247. Theodoropoulos DS, Ledford DK, Lockey RF, Pecoraro DL, Rodriguez JA, Johnson MC,

Boyce HW:

Upper Airway Symptoms in Gastroesophaeal Reflux Disease.

American Academy of Allergy Asthma and Immunology 56th Annual Meeting, San

Diego, California, March 3 - March 8, 2000.


*248. Kumar M, Behera AK, Lockey RF, Mohapatra SS:

The Adjuvant Role of IFN-y and IL-12 Plamid DNAs in a Grass Allergen Vaccine.


Diego, California, March 3 – March 8, 2000.


*249. Kong X, Matsuse H, Hu J, Wolf S, Lockey RF, Mohapatra SS:

IL-12 Mediated Th2 to Th1 Shift in a Murine Model of Grass Allergy is Associatd

with Differential IL-12 Receptor Expression.




36

*250. Jaen C, Codina R, Lockey RF:

Presence of Bla g2 Allergens in Store Purchased Flour Samples.




*251. Codina R, Jaen C, Lockey RF, Arduso L, Crisci C, Bertoya N:

Increased Allergenicity of Fresh Soybean Hulls After Three Weeks of Storage.




*252. Chandra S, Codina R, Beal D, Lockey RF:

Dust Mite Allergen Prevention in New Homes in Hot, Humid Climates Using

Thorough Vacuum Cleaning and Central Air Conditioning and Dehumidification.




*253. Behera AK, Kumar M, Lockey RF, Mohapatra SS:

Interferon-y Inhibits Respiratory Syncytial Virus Infection in Hep-2 Epithelial Cells

by Upregulation of 2’-5’ Oligoadenylate Cascade.




*254. Lockey RF, Reichmuth D, Codina R, Jaen C:

Ferret Allergy.




*255. Bukantz SC, Mohapatra SS, Zhang J, Leparc G, Lockey RF:

Induction of IgE-Specific for Blood Group Antigens.




*256. Kuderer NM, San Juan HG, Kong X, Esch R, Lockey RF, Mohapatra SS:

Allergen-Induced Production of Interleukin-8 By Human Airway Epithelial Cells

Involves Activation of p44/42 Map Kinase.

American Thoracic Society 2000 International Conference, Toronto, Canada, May 5-

10, 2000.

Am J Resp & Crit Care Med, 161(3):A895, March 2000.

*257. Mohapatra SS, Lockey RF, Matsuse H, Behera A, Kumar M:

Recurrent respiratory syncytial virus infection promotes development of asthma.

XVII International Congress of Allergology and Clinical Immunology, Sydney,

Australia, October 15-20, 2000.

Allergy & Clinical Immunology (ACI) International, Suppl 2:34, 2000.

37

*258. Mohapatra SS, Lockey RF, Matsuse H, Kong X, Hu J:

IL-12 as a vaccine adjuvant in allergic disease.

XVII International Congress of Allergology and Clinical Immunology, Sydney,

Australia, October 15-20, 2000.

Allergy & Clinical Immunology (ACI) International, Suppl 2:27, 2000.

*259. Bukantz SC, Mohapatra SS, Leparc GF, Zhang J, Newton C, Lockey RF:

Synthesis of antibodies to the ABO and lewis antigens by mice immunized with

human blood group O saliva.

5th Annual Conference of the society for Glycobiology, Boston, MA, November 8-11,

2000.

Glycobiology, 10(10):1114, 2000.

*260. Codina R, Lockey RF, Ardusso L, Crisci C, Bertoya N:

Identification of the soybean hull allergens involved in sensitization to soybean dust in

a rural population from Argentina and N-terminal sequence of a major 50 KD

allergen.

American Academy of Allergy Asthma and Immunology 57th Annual Meeting, New

Orleans, Louisiana, March 16 – March 21, 2001.

J Allergy Clin Immunol 107(2):S23, February 2001.

*261. Lockey RF, Codina R, Zhang J, Mohapatra SS, Brenner RJ:

Standardizaiton of a technique to measure Dermatophagoides farinae antigens in dust

samples using rabbit-polyclonal antibodies.




*262. Theodoropoulos DS, Ledford DK, Lockey RF, Pecoraro DL, Rodriguez JA, Johnson MC, Boyce

HW:

Gastroesophageal Reflux Disease (GERD) Associated Symptom Scores Correlate with

numbers of Reflux Episodes. American Academy of Allergy Asthma and Immunology

57th Annual Meeting, New Orleans, Louisiana, March 16 – March 21, 2001.


*263. Luck TW, King MJ, Reichmuth DA, Crockett RE, Lockey RF:

Correlation between a positive D. Pteronyssinus prick puncture skin test and a

positive nasal challenge in older vs. younger subjects.




*264. San Juan H, Kuderer NM, Esch R, Lockey RF, Mohapatra SS:

Allergen-inducd production of interleukin-8 by human airway epithelial cells involves

activation of P44/P42 map kinases.




38

*265. Kong X, San Juan H, Kumar M, Lockey RF, Mohapatra SS:

Respiratory syncytial virus-induced early gene expression involves activation of stat 1

Gα and map kinases in A549 epithelial cells.




*266. Kumar M, Behera AK, Zhang J, Lockey RF, Mohapatra SS, Perez-Dela Cruz C, Lin J, Leong

KW, Huang SK:

A RSV genome chitosan nanosphere (RGCN) vaccine against respiratory syncytial

virus (RSV) infection.





Mechanism of interferon-γ inhibition of respiratory syncytial virus infection of human

epithelial cells.




*268. King MJ, Luck TW, Reichmuth DA, Crockett RE, Lockey RF:

The effect of age and sun damage on allergy skin test results.



J Allergy Clin Immunol 107(2):S254, February 2001

*269. Crockett RE, Lockey RF:

Anaphylaxis from parenteral thiamine self-administered at home.




*270. Lockey RF (participating investigator):

Fluticasone Propionate/Salmeterol HFA MDI Has a Rapid Onset of

Effect in Asthmatics Treated with Short-Or Long-Acting Beta2-Agonists (BA) or

Inhaled Corticosteroids (ICS). American Thoracic Society Annual Meeting, San

Francisco, CA, May 23, 2001.

*271. Hicks M, Reichmuth D, Lockey RF, Bielsa L, Good R, Day N:

Factor I Complement Deficiency in an Individual of Parents with Normal Factor I.

AAAAI 58th Annual Meeting, New York City, March 1-6, 2002.


Mucosal 2’-5’ Oligoadenylate Synthetase (2-5 AS) Gene Transfer Attenuates

Respiratory Syncytial Virus Infection in a Murine Model.

J Allergy Clin Immunol 109(1): S43, January, 2002.

*273. Kumar M, Behera AK, Lockey RF, Mohapatra SS:

Role of Mucosal IFN-Ƴ Gene Transfer on Allergic Sensitization and RSV Infection.


39

*274. Godfrey SG, Codina R, Diwadkar R, Mobley LL, Lockey RF:

Dust Mite Numbers in Central Florida Homes and their Association with Home

Characteristics.


*275. Huang S-K, Li XD, Liu MC, Lockey RF, Mane S, Mohapatra SS:

Microarray Analysis of Gene Expression in Bronchioalveolar Lavage Cells of

Subjects with Asthma Following Segmental Allergen Challenge.


*276. Ramirez NC, Lockey RF, Fox RW, Kornfeld SJ:

Melkerson-Rosenthal Syndrome: A Rare Cause of Orofacial Edema.

J Allegy Clin Immunol 109(1): S129, January, 2002.

*277. Hicks RM, Reichmuth D, Lockey RF, Bielsa L, Good RA, Day NK:

Factor I Complement Deficiency in an Individual of Parents with Normal

Factor I.


*278. Diwadkar R, Codina R, Mobley LL, Lockey RF:

Study of the Possible Interference of Disodium Ovtaborate Tetrahydrate (DOT),

Carpet Shampoo, and Boric Acid on the Measurement of Der F1 and Der P1 in Dust

Samples by ELISA using Monoclonal Antibodies.


*279. Kong X, Patton G, Kumar M, Behera AK, Zhang J, Lockey RF, Mohapatra SS:

An Immunocompromised BALB/c Mouse Model for Respiratory Syncytial Virus

Infection.


*280. Nagy SB, Randall TS, Lockey RF, Mohapatra SS:

Respiratory Syncytial Virus Infection and Asthma Link: Role of Dendritic Cells.


*281. San Juan HG, Lockey RF, Mohapatra SS:

Activation of PKC Isozymes in Normal Human Bronchial Epithelial Cells by

Respiratory Syncytial Virus Infection.


282. Hellermann F,Kong X, Nagy S. Lockey RF, Mohapatra SS:

Exposure of human epithelial cells to cigarette smoke condensate elicits a

proinflammatory response involving the MAPK and NFĸ-B signaling pathways.

98th ATS International Conference, Atlanta GA, May 2002.

283. Mohapatra SS, Lockey RF, Behera AK, Kumar M:

[A57] [Poster: A8] Mucosal IFN-gamma gene transfer attenuates on allergic

sensitization, airway hyperresponsiveness and RSV infection. Mucosal IFN-

gene transfer attenuates allergic sensitization, airway hyperresponsiveness and

RSV infection.

98th ATS International Conference, Atlanta GA, May (A57), 2002.

40

284. Behera AK, Kumar M, Lockey RF, Mohapatra SS:

Adenovirus-mediated IFN-g gene transfer inhibits established allergen-induced

inflammation and airway hyperractivity in BALB/c mice.

98th ATS International Conference, Atlanta GA, May[LB1] [Poster: C124], 2002.

285. Codina R, Diwadkar R, Mobley LL, Lockey RF:

Environmental assay to measure cat flea (Ctenophalides felis) antigens in dust

samples using polyclonal antibodies.

Indoor Air 2002, the 9th International Conference on Indoor Air Quality and

Climate, Monterey, CA, July, 2002.

286. Lockey RF, Meeves S, Liao Y, Georges G:

Fexofenadine 180 mg and Cetirizine 10 mg Demonstrate a Similar Effect on Total

Symptom Score. 59th American Academy of Allergy Asthma & Immunology Meeting

in Denver, CO, March 7-12, 2003.

J Allergy Clin Immunol 2003;111(2):S356.

287. Ardusso LRF, Codina R, Crisci CD, Lockey RF, et al:

Skin Sensitivity to Aspergillus flavus in Patients with Soybean Induced Asthma

and/or Allergic Rhinitis. 59th American Academy of Allergy Asthma &

Immunology Meeting, Denver, CO, March 7-12, 2003.

J Allergy Clin Immunol 2003;111(2):S356.

288. Hellermann G, Kong X, San Juan H, Lockey RF, Mohapatra SS:

Chitosan IFN-gamma-gene Nanosphere (CIN) Therapy for Allergic Asthma:

Modulation of Specific T-Cell and Dendritic Cell Responses.

59th American Academy of Allergy Asthma & Immunology Meeting, Denver,

CO, March 7-12, 2003.

J Allergy Clin Immunol 2003:111(2):S392.

289. King MJ, Bukantz S, Phillips S, Mohapatra SS, Randall TS, Lockey RF:

Serum Total IgE and Specific IgE to D. pteronyssinus, but not Eosinophilic

Cationic Protein (ECP), Are More Likely to be Elevated in Elderly Asthmatics.


CO, March 7-12, 2003.

J Allergy Clin Immunol 2003;111(1) (Supplement 2): S309.

290. Mohapatra SS, Kumar M, Behera A, Hellermann G, Lockey RF, Vesely D:

Intranasal Atrial Natriuretic Peptide (ANP) Gene Transfer Attenuates Airway

Reactivity in a Mouse Model of Allergic Asthma


CO, March 7-12, 2003.

J Allergy Clin Immunol 2003; 111(1) (Supplement 2): S309.

291. Kong X, Kumar M, Behera A, Hellermann G, Lockey RF, Mohapatra SS:

Chitosan IFN-gamma-gene Nanoparticle (CIN) Therapy for Allergic Asthma in mice

involves STAT4 signaling pathway.

59th American Academy of Allergy, Asthma & Immunology Meeting, Denver, CO,

March 7-12, 2003.

J Allergy Clin Immunol 2003;111(1) (Supplement 2): S354.

41

292. McKnight S, Fox RW, Crockett RE, Lockey RF:

Anaphylactic Reaction to High Dose Methotrexate with Successful

Desensitization. 59th American Academy of Allergy Asthma & Immunology Meeting,

Denver, CO, March 7-12, 2003.

J Allergy Clin Immunol 2003;111(2):S288. (#879)

293. Schroer B, Lockey RF:

Oral tacrolimus for severe recalcitrant atopic eczema. J Allergy Clin Immunol 2003;

111(6):1409.

294. Lockey RF, Abreu P, Kimel M, Sacks H:

Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF

DPI) in patients with mild to moderate persistent asthma previously using inhaled

corticosteroids. European Respiratory Society (ERS), Vienna 2003 Annual Congress,

September 28-29, 2003


Synthesis of an antagonistic natriuretic peptide in the lung attenuates allergic

asthma in mice, World Allergy Organization Congress – XVIII ICACI (WAO) in

Vancouver, Canada, September 7-12, 2003.

296. San Juan Vergara HG, Lockey RF, Mohapatra SS:

Inhibition of PKC-Alpha Activity Blocks Respiratory Syncytial Virus Infection.

60th American Academy of Allergy Asthma & Immunology Meeting, San

Francisco, CA, March 19-23, 2004.


297. Hellermann G, Gunnarsdottir J, Kong X, San Juan H, Singam R, Behera S, Zhang W,

Lockey RF, Mohapatra SS:

Mechanism of Bronchoprotective Effects of a Novel Natriuretic Horomone

Peptide.




298. Kong X, San Juan H, Behera A, Lockey RF, Mohapatra SS:

Cross-Talk Between ERK-1/2 and STAT-1-Alpha Pathways in Respiratory

Syncytial Virus-Induced Early Gene Expression in Human Epithelial Cells.




299. Singam RV, Kong X, Hellermann G, San Juan H, Behera S, Zhang W, Jena PK,

Lockey RF:

Chitosan Nanoparticle-Mediated De Novo Synthesis of a Novel Natriuretic Hormone

Peptide Reverses Established Asthma in Mice.




42

300. Zhang W, Yang H, San Juan H, Singam R, Kong X, Hellermann G, Lockey RF, Peeples

ME, Mohapatra SS:

Inhibition of Respiratory Syncytial Virus Replication by Vector-Derived Small

Interfering RNAs Against NS1 Protein.



J Allergy Clin Immunol 2004;113(2):S330. (#1225).

301. Singam R, Ledford D, Lockey RF, Mohapatra SS:

The use of fluticasone propionate (FP) with salmeterol (S) is a more effective

treatment than FP alone for respiratory syncytial virus (RSV) infection-induced

airway inflammation in the presence or absence of allergen sensitization. ATS

2004 International Conference, May 21-26, Orlando, Florida. Amer Journal of

Resp & Critical Care Med, official Journal of American Thoracic Society (ATS),

169(7) p. A126, April, 2004.

302. Mohapatra SS, Singam R, Kong X, Behera S, Hellermann G, Mohapatra S, San Juan H,

Jena PK, Yang H, Zhang W, Lockey RF:

Chitosan lipid nanoparticles (CLNs) augment gene delivery and expression in

mice. Controlled Release Society 31st Annual Meeting Transactions. #234, 2004.

*303. DeMarco PJ, Codina R, Bagg AS, Fox RW, Lockey RF:

Indoor levels of fungal spores in Central Florida homes without obvious moisture

problems. 61st American Academy of Allergy, Asthma & Immunology Annual

Meeting, San Antonio, TX, March 18-22, 2005.

J Allergy Clin Immunol 2005; 115(2):S20. (#81)

*304. Zhang W, Yang H, Behera S, Kong X, Lockey RF, Mohapatra SS:

Prophylaxis of respiratory syncytial virus infection with intranasal siRNA-

Nanoparticles of the NS1 gene in vivo. 61st American Academy of Allergy, Asthma &

Immunology Annual Meeting, San Antonio, TX, March 18-22, 2005.

J Allergy Clin Immunol 2005; 115(2): S135. (#540).

*305. Kong X, Zhang W, Lockey RF, Auais A, Piedemont G, Mohapatra SS:

Short interference RNA for RSV-NS1 gene attenuates virus infection in Fischer

344 rats. 61st American Academy of Allergy, Asthma and Immunology Annual

Meeting, San Antonio, TX, March 18-22, 2005.


*306. Bagg AS, Ledford DK, Lockey RF:

Progesterone associated angioedema and vasculitis. 61st American Academy

of Allergy, Asthma and Immunology Annual Meeting in San Antonio, TX,

March 18-22, 2005.

J Allergy Clin Immunol 2005; 115(2), S105. #420.

*307. San Juan Vergara H, Cuevas J, Lockey RF, Mohapatra SS:

Role of calcium in PKC- activation and RSV infection of normal human

bronchial epithelial (NHBE) cells. 61st American Academy of Allergy,

Asthma and Immunology Annual Meeting, San Antonio, TX, March 18-22,

2005.

J Allergy Clin Immunol 2005; 115(2), S141, #564.

43

*308. Hellermann GR, Lockey RF, Mohapatra SS:

Oral Administration of a Chitosan/Ovalbumin Peptide Complex Reduces the

OVA-Specific Allergic Response in BALB/c Mice. ATS 2005 International

Conference May 20-25, San Diego, CA, Proceedings of the American Thoracic

Society, Official publication of the American Thoracic Society (ATS), 2: p. A83,

2005.

*309. Kong X, Zhang W, Lockey R, Auais A, Piedimonte G, Mohapatra S:

Intranasal Delivery of Chitosan RNAi Nanoparticles for RSV-NS1 Gene

Attenuates Pulmonary Infection and Inflammation in Fischer 344 Rats and

BALB/c Neonates. ATS 2005 International Conference May 20-25, San Diego,

CA, Proceedings of the American Thoracic Society, Official publication of the

American Thoracic Society (ATS), 2: p. A453, 2005.

*310. Singam R, Jena PK, Behera S, Ledford D, Lockey RF, Mohapatra SS:

Combined Therapy of Fluticasone Propionate (FP) with Salmeterol (S) in a

Murine Model of Allergen and Respiratory Syncytial Virus-Induced Asthma.

ATS 2005 International Conference May 20-25, San Diego, CA, Proceedings of

the American Thoracic Society, Official publication of the American Thoracic

Society (ATS), 2: p. A603, 2005.

311. Mohapatra S, Lockey RF, Kong X, Singham R, Behera S, Jena P, Hellermann G, Zhang W:

Modulation of asthma by natriuretic peptide nanoparticles: Role of treg cells.

XIXth World Allergy Organization Congress, XXIVth Congress of the European

Academy of Allergology and Clinical Immunology, Munich, Germany, June 26-

July 1, 2005, Journal of the World Allergy Organization, (suppl 1) p 561, 2005.

*312. Ramey J, Lockey RF:

Preseptal cellulites secondary to a dental abscess. Southeastern Allergy

Conference, Hilton Head, SC, October, 2004.

Allergy Clin Immunol Int: J World Allergy Org, January, 2006, 18(1): 20-21.

*313. Jones AR, Beckstead JW, Lockey RF, MohapatraSS:

Cigarette Smoke-induced Gene Expression Analysis in Normal Human Bronchial

Epithelial Cells. 62nd Annual American Academy of Allergy, Asthma & Immunology

Meeeting, Miami, FL, March 3-7, 2006.

J Allergy Clin Imunol 2006; 117(2): S26. (#101).

*314. Vu At, Glaum MC, Naik EG, Grandstaff M, Shah NM, Panagos P, Franck R, Ramey JT,

Lockey RF:

Impact of an Asthma Educational Program on Children at an Asthma Camp. 62nd

Annual American Academy of Allergy, Asthma & Immunology Meeting, Miami, FL,

March 3-7, 2006.


*315. Esch RE, Bush RK, Peden D, Lockey RF:

Sublingual-oral Administration of Standardized Allergenic Extracts/Vaccines: Safety

and Dosing Studies. 62nd Annual American Academy of Allergy, Asthma &

Immunology Meeting, Miami, FL, March 3-7, 2006.


44

*316. Ramey JT, Rosenbach KP, Shah M, Ledford DK, Lockey RF:

Leukocytoclastic Vasculitis and Truncal Erythroderma: two case reports of adverse

skin reactions to technetium-99m sestamibi (Tc-99m-S). Florida Allergy, Asthma and

Immunology Society (FAAIS) Meeting, Boca Raton, FL, June 10-12, 2005, and

American College of Allergy, Asthma and Immunology (ACAAI) Meeting, Anaheim,

CA, November 4-9, 2005.

Annals of Allergy, Asthma & Immunology 2006; 96(1):226.

*317. Ramey J, Lockey RF:

Possible allergic reaction to sublingual and transdermal nitroglycerin.

Florida Allergy, Asthma, and Immunology Society Conference, Naples, FL,

June, 2004.

Allergy Asthma Proc (review article), 2006; 27(3).

*318. Chacko T, Glaum M, Lockey RF:

Asymptomatic Healthy Adult with Persistent Eosinophilia (1st prize abstract award).

Florida Allergy, Asthma & Immunology Society annual meeting, Kissimmee, FL,

June 8, 2006.

*319. Cole SF, Lockey RF:

Primary Gastrointestinal Lymphangiectasia Presenting as Cryptococcus Meningitis”.

Florida Allergy, Asthma & Immunology Society annual meeting, Kissimmee, FL,

June 8, 2006.

*320. Glaum M, Nimal S, Lockey RF, Mohapatra, SS:

Atrial Natriuretic Peptide Activates Human Mast Cells via an Ige-Independent

Mechanism. Presented at the FOCUS conference (Federation of Clinical Immunology

Societies), San Francisco, CA, June 2, 2006.

Clin Immunol 2006; 19:S53.

*321. Glaum MC, Nimal S, Lockey RF, Mohapatra SS:

Atrial Natriuretic Peptide is Released from Human Mast Cells following IgE-

Mediated Activation. 63rd Annual American Academy of Allergy, Asthma &

Immunology Meeting, San Diego, CA, February 23 – 27, 2007.


*322. Nimal S, Glaum MC, Jena PK, Lockey RF, Mohapatra SS:

Atrial Natriuretic Peptide can Modulate Human Mast Cell Gene Expression. 63rd

Annual American Academy of Allergy, Asthma & Immunology Meeting, San Diego,

CA, February 23 – 27, 2007.


*323. Wang X, Xu W, Kong X, Shirley S, Lockey RF, Mohapatra SS:

siRNA Targeting the Natriuretic Peptide Receptor-A Prevents Airway Inflammation

in a Mouse Model of Allergic Asthma. 63rd Annual American Academy of Allergy,

Asthma & Immunology Meeting, San Diego, CA, February 23 – 27, 2007.


*324. Chacko T, Glaum M, Ledford D, Fox R, Lockey RF:

Systemic Reactions to Percutaneous (P) and Intradermal (ID) Skin Tests

(ST). 63rd Annual American Academy of Allergy, Asthma & Immunology Meeting,

San Diego, CA, February 23 – 27, 2007.


45

*325. Kong X, Wang X, Hellerman G, Lockey RF, Mohapatra SS:

Mice Deficient in Atrial Natriuretic Peptide Receptor A (NPRA) Exhibit Decreased

Lung Inflammation: Implication of NPRA Signaling in Asthma Pathogenesis. 63rd


CA, February 23 – 27, 2007.


*326. Chacko T, Ledford D, Lockey RF:

Fever of Unknown Origin (FUO) and Anemia as Sole Presenting Features of

Sarcoid. 63rd Annual American Academy of Allergy, Asthma & Immunology

Meeting, San Diego, CA, February 23 – 27, 2007.


*327. Chacko T, Frank R, Ledford D, Lockey RF:

Churg-Strauss Presenting as Pulmonary Embolism, Lymphadenopathy and

Eosinophilia. 63rd Annual American Academy of Allergy, Asthma & Immunology



*328. Zhang W, Cao X, Hellermann G, Lockey RF, Mohapatra SS:

Atrial Natriuretic Peptide (ANP)-mediated Maturation and Cytokine Phenotype of

Human Dendritic Cells (DCs) Involve Demethylation of the SOCS3 Promoter. 63rd


CA, February 23 – 27, 2007.


*329. Cao X, Zhang W, Lockey RF, Mohapatra SS:

ANP-NPRA Signaling Modulates Immunity by Altering TLR-2 Expression in Human

Dendritic Cells (DCs). 63rd Annual American Academy of Allergy, Asthma &

Immunology Meeting, San Diego, CA, February 23 – 27, 2007.


*330. Shin B, Ledford DK, Lockey RF:

Abdominal Pain, Nausea, and Vomiting as the Initial Presenting Symptoms

of Systemic Lupus Erythematosus. 63rd Annual American Academy of Allergy,

Asthma & Immunology Meeting, San Diego, CA, February 23 – 27, 2007.


*331. Bensch GW, Corren J, Lockey RF, Yao R, Staudinger H:

Rescue-Free and Symptom-Free Days with Mometasone Furoate Dry Powder

Inhaler Used Once or Twice Daily in the Evening by Patients with Persistent

Asthma. 63rd Annual American Academy of Allergy, Asthma & Immunology



332. Jones AR, Nimal S, Lockey RF, Mohapatra SS:

Microarray Analysis of Cigarette Smoke Condensate-Induced Changes in Normal

Human Bronchial Epithelial Cells.

Am J Resp Crit Care Med 2007; 175:A885.

46

*333. Busse W, Weiler J, Murray J, Schwartz L, Katial R, McFadden ER, Lockey RF, Barrett RJ:

Administration of Binodenoson, A Selective Adenosine A2a Receptor Agonist

Pharmacologic Stress Agent, is Safe in Asthmatics. Annual Meeting of the American

Society of Nuclear Cardiology, San Diego, CA, September 6 – 9, 2007.

J Nuclear Cardiology 2007;14(4): S102. (#1.14).

334. Hanania NA, Holbrook J, Reibman J, Ramsdell J, Wise R, King MJ, Lockey RF (participant):

Characteristics of Elderly Asthmatics Participating in Asthma Clinical Trials.

From the Asthma Cliniclal Research Centers sponsored by the American Lung

Association / American Thoracic Society Annual Meeting, May 18-23, 2007, San

Francisco, CA.

*335. Shirley S, Montpetit AJ, Lockey RF, Mohapatra SS:

Curcumin Modulates LPS-Induced Inflammation in Human Dendritic Cells.

64th Annual American Academy of Allergy, Asthma & Immunology Meeting,

Philadelphia, PA, March 14 – 18, 2008.


*336. Bagg A, Chacko T, Lockey RF, Ledford D, Fox R, Glaum M:

Systemic Reactions to Percutaneous and Intradermal Skin Tests

Poster presentation, World Allergy Organization’s 20th World Allergy Congress

(WAC), in partnership with The Asia Pacific Association of Allergy, Asthma & Clinical

Immunology (APAAACI), The Allergy and Immunology Society of Thailand (AIST),

and the West-Pacific Allergy Organization (WPAO), Bangkok, Thailand, December 2 –

6, 2007.




*337. Wang X, Xu W, Chen D, Kong X, Lockey RF, Mohapatra SS:

Modulation of Lung Inflammation by Vessel Dilator, an N-Terminal Natriuretic

Peptide, in a Mouse Model of Allergic Asthma.




*338. Kong X, Song S, Wang X, Xu W, Shirley S, Lockey RF, Mohapatra SS:

Bone Marrow Derived Stem Cells Reduce Lung Inflammation in a Mouse Asthma

Model.




*339. Lockey RF, Hampel F:

Once-Daily is Equivalent to Twice-Daily Treatment with Mometasone Furoate Dry

Powder Inhalation in Patients with Persistent Asthma.




47

*340. Zhang W, Cao X, Hellermann G, Kong X, Chen D, Wang J, Lockey RF, Mohapatra SS:

Mechanism of Atrial Natriuretic Peptide Receptor (NPRA) – Mediated Induction of

Tolerogenic Dendritic Cell (DC).




*341. Shin B, Davis Y, Kong X, Park SJ, Lockey RF, Mohapatra SS:

SiRNA for Intercellular Adhesion Molecule-1 (ICAM-1) Decreases Infection of A549

Cells by Respiratory Syncytial Virus (RSV) and Human Rhinovirus (HRV)-16.




*342. Glaum MC, Liu G, Lockey RF, Mohapatra SS:

Identification of a Stable Human Mast Line Derived from Human Cord Blood Stem

Cells.




*343. Montpetit AJ, Shirley SA, Lockey RF, Mohapatra SS:

Cigarette Smoke Condensate affects Dendritic Cell (DC) Maturation by Modulating

DC-Epithelial Cell Cross-Talk.




*344. Wang J, Zhang W, Wang X, Lockey RF, Mohapatra SS:

Role of MicroRNAs in the Pathogenesis of Asthma.



J Allergy Clin Immunol 2008; 121(2): S262 (#1014).

*345. Kong XY, Hellermann GR, Zhang WD, Jena PK, Kumar M, Behera A, Behera S,

Lockey RF, Mohapatra SS:

Chitosan IFN-Gamma Nanogene (CIN) Therapy for Lung Disease: Modulation of T

Cell and Dendritic Cell Immune Responses.

2008 American Thoracic Society International Conference, Toronto, Canada, May 16-

21, 2008.

American J Resp Crit Care Med 2008; 177: A77.

*346. Garay SM, Bensch GW, Lockey RF:

Rapid Reduction of Nocturnal Awakenings with Inhaled Mometasone Furoate in

Adults with Mild to Moderate Persistent Asthma.

American Thoracic Society International Conference, Toronto, Canada, May 16-21,

2008.

American J Resp Crit Care Med 2008; 177: A616.

48

*347. Phillips JF, Bagg AS, Lockey RF:

Systemic Reactions (SRs) to Subcutaneous Allergen Immunotherapy (SCIT) and the

Response to Epinephrine.


Washington, DC, March 13 – 17, 2009.


*34 8. Wang J, Zhang W, Li K, Chen D, Liu G, Lockey RF, Mohapatra SS:

Npr1 Deficiency Upregulates Regulatory T Cells (Tregs) Through Impaired Dendritic

Cell (DC) Development.




*349. Shin B, Cole SL, Park S, Ledford DK, Lockey RF:

A New Symptom Based Questionnaire for Predicting Asthma.




*350. Glaum MC, Liu G, Lockey RF, Mohapatra SS:

Mediator Release from a New Human Mast Cell Line (USF-MC1).




*351. Kumar A, Vo D, Davis Y, Lockey RF, Mohapatra SS:

A Novel Microfluidic Assay for Detection of Breath Biomarkers.




*352. Boyapalle S, Zhang W, Cao X, Lockey RF, Mohapatra SS:

Nuclear Trafficking and Regulation of Innate Immunity by Respiratory Syncytial

Virus (RSV) NS1 protein.




*353. Zhang W, Boyapalle S, Cao X, Wang J, Lockey RF, Mohapatra SS:

RSV NS1 Protein Blocks the IFN Response by Blocking RIG-I Interaction with the

Mitochondrial Antiviral Signaling Protein. MAVS.




*354. Kong X, Zhang W, Jena PK, Lockey RF, Mohapatra SS:

Natriuretic Peptide Signaling Pathway Involvement in Respiratory Syncytial Virus

Infection of Lung Epithelium.




49

355. Glaum MC, Liu G, Wang JW, Lockey RF, Mohapatra SS:

Cytokine mRNA expression and SV40 transfection of a new human mast cell line

(USF-MC1).

2009 World Allergy Congress Meeting, December 6 – 10, 2009, Buenos Aires,

Argentina.

*356. Kumar A, El-Badri N, Lockey RF, Mohapatra S, Cameron DF:

Sertoli Cell Mediated-Targeted Drug Delivery To The Lungs.

66th Annual American Academy of Allergy, Asthma & Immunology Meeting, New

Orleans, LA, February 26 – March 2, 2010.

J Allergy Clin Immunol 2010; 125(2): AB6. (#24).

*357. Wang J, Li K, Zhang W, Lockey RF, Mohapatra S, Mohapatra SS:

Over-expression of MiRRA2 in vivo Impairs T Lymphocyte

Activation




*358. Rael EL, Ramey JT, Lockey RF:

Oxymetazoline (OXY) Hydrochloride Combined with Mometasone Nasal Spray

(MNS) for Persistent Nasal Congestion (NC)




*359. Glaum MC, Liu G, Wang J, Lockey RF, Mohapatra SS:

Degranulation, Cytokine mRNA Expression and SV40 Transfection of an SCF-

independent Human Mast Cell Line (USF-MC1)




*360. Zhang W, Cao X, Chen D, Wang J, Yang H, Mohapatra S, Hellermann G, Kong X, Lockey

RF, Mohapatra SS:

Atrial Natriuretic Peptide Receptor Signaling Plays a Critical Role in Induction of

Tolerogenic Dendritic Cells



J Allergy Clin Immunol 2010; 125(2): AB227 (# 891).

*361. Butt A, Alkhalil M, Ledford D, Lockey RF:

Methotrexate for Urticarial Vasculitis and Angioedema with Cryoglobulinemia.

Submitted, WAO International Scientific Conference (WISC), December 5 – 8, 2010,

Dubai, UAE.

*362. Aljubran SA, Battula KK, Jalali S, Mohapatra S, Lockey RF, Kolliputi N:

Enhancer of Zeste Homolog 2: APivotal Role in Pulmonary Artery Smooth Muscle

Cell Proliferation?

Submitted, American Thoracic Society (ATS) meeting, Denver, Colorado, May 13-18,

2011.

50

*363. Wang J, Li K, Lockey RF, Mohapatra S, Mohapatra SS:

Sensitive and Specific Universal RT-qPCR Profiling of miRNAs.

67th Annual American Academy of Allergy, Asthma & Immunology Meeting, San

Francisco, CA, March 18 – 22, 2011.


*364. Zuraw B, Craig T, Lockey RF, Park M, Grant J, Suez D, Schwartz LB, Riedl M, Levy RJ, Li

HH, Edara L, Bernstein JA, Moy J, Offenberger J, Szema A, Engler A, et al:

Clinical Outcomes with Recombinant Human C1 Inhibitor in the Repeat Treatment of

Acute Attacks of Hereditary Angioedema in North-American Patients.

67th Annual American Academy of Allergy, Asthma & Immunology Meeting, San

Francisco, CA, March 18 – 22, 2011.


*365. Lockey RF:

Asthma and Comorbidity.

XVI International Congress on Rehabilitation in Medicine and Immunorehabilitation,

Paris, France, April 30 – May 3, 2011.

International Journal on Immunorehabilitation 2011; 13(1): 32.

*366. Lockey RF:

Asthma in the Elderly.

XVI International Congress on Rehabilitation in Medicine and Immunorehabilitation,

Paris, France, April 30 – May 3, 2011.

International Journal on Immunorehabilitation 2011; 13(1): 32.

367. Talreja N, Culverhouse S, Shearer D, Lockey RF:

A Case of Idiopathic Recurrent Isolated Orbital Angioedema with Exophthalmos.

XXII World Allergy Congress, Cancun, Mexico, December 4 – 8, 2011.

368. Butt A, Rashid D, Fox R, Lockey RF:

Urticaria and Arthralgias in a Nine-Year Old with Recurrent Urinary Tract Infections.


World Allergy Organization Journal 2012; 5 (Suppl 2): S139, February 2012.

369. King MJ, Fitzhugh D, Lockey RF:

Photoaging Attenuates Skin Test Response to Histamine more than Natural Aging.


*370. Aljubran S, Cox R, Tamarapu P, Lockey RF, Kolliputi N:

Enhancer of Zeste Homolog 2: A Pivotal Role in Pulmonary Artery Smooth Muscle

Cell Proliferation.


*371. Nelson A, Parkerson J, Lockey RF, Mohapatra SS, Mohapatra S, Nagaraj S:

Role of Myeloid Derived Suppressor Cells in Asrhma.


*372. Wang J, Li K, Hellermann G, Lockey RF, Mohapatra SS, Mohapatra S:

Mir-150 Suppresses Lung Inflammation in a Mouse Model of Experimental Asthma.


51

*373. Wang J, Li K, Lockey RF, Mohapatra SS, Mohapatra S:

A Highly Sensitive and Specific Universal Mirna Profiling Method.


374. Shearer D, Lockey RF, Fox R, Ledford D, Glaum M:

Incidence of Systemic Reactions (SRs) to Prick (P) and Intradermal (ID) Tests,

Response to Immediate (“Stat”) Epinephrine IM (epi IM)Dose Vs. BMI, Number of

Delayed SRs, and WAO Systemic Reaction Grade.


*375. Cox Jr, R, Aljubran S, Lockey RF, Kolliputi N:

Caspase-4 Plays a Role in the Activation of the Cryopyrin/NLRP3 Inflammasome.


*376. Alkhalil M, Shearer D, Hattaway S, Fox R, Glaum M, Ledford D, Lockey RF:

Body Mass Index (BMI) and Immediate (“Stat”) Dose of Epinephrine IM (epi IM)

Needed to Treat Subcutaneous Allergen Immunotherapy (SCIT) Systemic Reactions

(SRs).


377. Alkhalil M, Varghese M, Hellermann G, Mohapatra SS, Butt A, Lockey RF:

Measurement of Long-Acting Natriuretic Peptide (LANP) in Exacerbation of Asthma.


*378. Talreja N, Jelks M, Haq M, Hellermann G, Ledford DK, Lockey RF:

Effect of Meteorological Parameters on Airborne Fungal Spore Counts: Sixteen Year

Study (1995 – 2010) in Sarasota, FL.

68th Annual American Academy of Allergy, Asthma & Immunology

Meeting, Orlando, FL, March 2 – 6, 2012.


*379. Aljubran SA, Cox R, Parthasarathy PT, Kr G, Mohapatra SS, Lockey RF, Kolliputi N:

Enhancer of Zeste Homolog 2 induces Pulmonary Artery Smooth Muscle Cell

Proliferation and Migration.




*380. King MJ, Fitzhugh DJ, Phillips SE, Lockey RF:

Photoaging Attenuates Skin Test Response to Histamine but not Morphine.




*381. Kandasamy R1, Hellermann GR, Mohapatra SS, Lockey RF:

Flavonoid-Rich Alcoholic Extract of Leaves of Achyranthes Aspera Reduces

Inflammation in a Murine Model of Ova-Induced Asthma




52

*382. Ramey SJ, Bozeman S, Ramey JT, Franck RL, Vu AT, Lockey RF, Walsh JE:

Ability of Medical Students and Allergists to Correctly Identify Flying Hymenoptera

Species.




*383. Wang J, Li K, Hellermann G, Mohapatra SS, Lockey RF, Mohapatra S:

MiR150 Transgenic Mice Exhibit Altered T Cell Response, Cytokine Profile and

Lung Inflammation.




*384. Dorsey MJ, Elizalde A, Perez EE, Sriaroon P, Nguyen D, Lockey RF, Sleasman JW:

Effectiveness of an Educational Intensive Course on Allergy and Immunology

Clinical and Diagnostic Procedures.




385. Calderon MA, Simons ER, Malling H, Lockey RF, Moingeon P, Demoly P:

Sublingual Allergen Immunotherapy: Mode of Action and its

Relationship with the Safely Profile.




*386. Lockey RF,Talreja N, Ledford DK:

Effect of Inhaled Corticosteroids with Long-Acting Beta2 Agonists vs. Inhaled

Corticosteroid Alone on Asthma Control in Children: Results from National Asthma

Survey (Poster).

XXIII World Allergy Organization International Scientific Congress (WISC),

Hyderabad, India, December 6– 9, 2012.

388. Cox RR, Phillips O, Fukumoto J, Parthasarathy PT, Fukumoto I, Luong T, Remsen N,

Lockey RF, Kolliputi N:

Resolvin D1 Attenuates Hyperoxia Induced Acute Lung Injury.

2013American Thoracic Society (ATS) conference, Philadelphia, PA, May 17 – 22,

2013.

*387. Marc Riedl, Dumitru Moldovan, Robyn Levy, James Baker, Krystyna Obtulowicz, Vesna

Grivcheva-Panovska, Don McNeil, Sladjana Andrejevic, Avner Reshef, Henriette Farkas,

Henry Li, Jonathan Bernstein, Aaron Davis, Richard Lockey, William Lumry, James Wedner,

Timothy Craig, Richard Gower, Todor Shirov, Anurag Relan, Marco Cicardi:

Recombinant Human C1 Inhibitor for Treatment of Acute Angioedema Attacks in

Patients with Hereditary Angioedema: a Randomized, Double-Blind, Placebo-

Controlled Clinical Trial.

European Academy of Allergy and Clinical Immunology & World Allergy

Organization World Allergy & Asthma Congress 2013, Milan, Italy, June 22 – 26,

2013.

53

*388. Shearer D, Lockey RF:

Epinephrine (E) for Self-Administration: Autoinjectors and Alternatives.


Meeting, San Antonio, TX, February 22 – 26, 2013.

J Allergy Clin Immunol (Suppl) 2013; 131(2): AB48 (#176).

*389. Cowan G, Talreja N, Fergeson JE, Jelks M, Ledford DK, Lockey RF:

The Effect of Local Temperature, Wind Velocity and Rain On Aerobiology Sampling;

Ten Year Study (2001-2011), Sarasota, Fl.




*390. Teng M, Fitzhugh DJ, Tran K, Lockey RF, Collins P:

Functional Characterization of A Cis-Acting Temperature Sensitive Mutation From A

Respiratory Syncytial Virus Vaccine Candidate.




*391. Talreja N, Ledford DK, Lockey RF:

Effect of Inhaled Corticosteroids (ICS) Vs. Inhaled Corticosteroid with Long-Acting

Beta2 Agonists (ICS/LABA) On Asthma Control: Results From National Asthma

Survey.




*392. Fergeson JE, Lockey RF, Glaum MC:

Presumed Type III Hereditary Angioedema Presenting with Recurrent Abdominal

Distention After Estrogen Use.




*393. Phillips O, Cox RR, Fukumoto J, Fukumoto I, Tamarapu P, Luong T, Lockey RF, Kolliputi N:

Inhibition of IL-1β Mediated Proinflammatory Cytokine Production by

Epigallocatechin Gallate in Human Alveolar Epithelial Cells




*394. Cox RR, Phillips O, Fukumoto J, Fukumoto I, Tamarapu P, Luong T, Lockey RF,

Kolliputi N:

Resolvin D1 Inhibits IL-1beta Induced Alveolar Epithelial Cell Activation




54

*395. Fukumoto J, Fukumoto I, Huynh B, Cox RR, Parthasarathy PT, Ramanathan GK,

Venugopal RB, Lockey RF, Kolliputi N:

NLRP3-Deficient Mice Have an Enhanced Neutrophil Apoptosis and a Suppressed

Inflammatory Response to Hyperoxia-Induced Acute Lung Injury.




*396. Talreja N, Cowan GM, Glaum M, LockeyRF:

Lymphopenia Induced by Etanercept.

The American College of Allergy, Asthma and Immunology (ACAAI) 2013 Annual

Scientific Meeting, Baltimore, Maryland, November 7 – 11, 2013.

*397. Pepper AN, Westermann-Clark E, Talreja N, Lockey RF:

Radiocontrast Media (RCM) Reactions: Fact versus Fiction.

Poster presentation, American College of Allergy, Asthma and Immunology 2013

Annual meeting, Baltimore, MD, November 7 – 11, 2013.

*398. Wang JW, Reiser M, Li K, Rifkin E, Wang B, Kolliputi N, Lockey RF:

LRBA Causes Immunodeficiency and autoimmunityby deregulating NFkB-Mediated

Multiple Immune Effectors Critical for B Cell Activation.


Meeting, San Diego, CA, February 28 – March 4, 2014.

*399. Pepper A, Westermann-Clark E, Talreja N, Lockey RF:

Radiocontrast Media Reactions: Rectifying Misconceptions about Shellfish Allergy

and Iodine “Allergy” in an Academic Institution.



*400. Glaum MC, Rifkin E, Wang JW, Lockey RF, Ledford DK:

Real-Time PCR Quantification of Virginia Live Oak (Quercus virginiana) Pollen.



*401. Livingston L, Cowan G, Lockey RF:

Inhaled Asthma Medications: Highlighting the Differences in Formulations and Use.



*402. Balduzzi M, Updegraff A, Rawson K, Taylor B, King MJ, Lockey RF:

Impulse Oscillometry (IOS) is Easier than Spirometry for Older Asthmatic and Non-

Asthmatic Subjects.



*403. Reiser M, Wang JW, Li K, Lockey RF:

LRBA Subcellular Localization: Evidence of the LRBA’s Role in Vesicle Trafficking

from the Golgi to Cell Membrane and Endocytosis.



55

*404. Yeomans K, Lockey RF, Nichol M, Kim H, Smith N, Allen-Ramey F, Blume S:

Administration of Subcutaneous Immunotherapy for Allergic Rhinitis in US Clinical

Practice.

Academy of Managed Care Pharmacy (AMCP) 26th annual meeting, April 1 – 4,

2014.

Journal of Managed Care Pharmacy (JMCP).

*405. Hankin CS, Lockey RF, Cox L, Najib M:

Allergic Rhinitis Frequently Remains Under-Diagnosed: Poorly-Controlled AR

Imposes Significant Burden.

EAACI Congress 2014, Copenhagen, Denmark, June 7 – 11, 2014.

TAPES:

1. One hour tape recordings - Medical Sciences Tape Library;

Sigma Information, Inc; 545 Cedar Lane; Teaneck, NJ 07666.

2. Series:

Lockey RF: Allergic Emergencies

Lockey RF: Immunopathologic reactions in human disease.

Lockey RF: Asthma and status asthmaticus.

3. Lockey RF: Participant, tape discussion based on selections from current literature, Journal

Club Allergy, Vol 2, #1, Omega Communications, Inc.; 110 Hillside Avenue; Springfield, NJ

07081, 1979.

4. Lockey RF: Discussion of book: Allergy and Clinical Immunology, RF Lockey, editor,

Journal Club Allergy, Vol 3, #1, Omega Communications, Inc.; 110 Hillside Avenue;

Springfield, NJ 07081, 1980.


Club Allergy, Vol 3, #2, Omega Communications, Inc.; 110 Hillside Avenue; Springfield,

NJ 07081, 1980.

6. Lockey RF: Participant, tape discussion based on selection from current literature, Journal


07081, 1981.



07081, 1982.



07081, 1984.

9. Lockey RF: Moderator and participant, tape discussion based on selections from current

literature, Journal Club Allergy, Vol 8, #3, Omega Communications, Inc.; 110 Hillside

Avenue; Springfield, NJ 07081, 1985.

56

10. Lockey RF: Moderator and participant, tape discussion based on papers presented at the

Annual Meeting of the American Academy of Allergy and Immunology, New Orleans, LA,

Journal

Club Allergy, Vol. 9, #2, Omega Communications, Inc.; 110 Hillside Avenue; Springfield, NJ

07081, 1986.

11. Lockey RF: Participant, Editors Corner, on paper "Fatalities Associated with Immunotherapy

and Skin Testing", Journal Club Allergy, Vol 9, #3, Omega Communications, Inc.; 110

Hillside Avenue; Springfield, NJ 07081, 1986.

12. One hour tape recording - Pharmacia Diagnostic, Piscataway, NJ 08854, 1986.

13. Lockey RF: Participant, "Practical Considerations During Hymenoptera Venom Treatment".

A scientific workshop held at the 36th annual meeting, the American Academy of Allergy,

February 16, 1986.

14. Lockey RF: Chairman, "Assessment and treatment of allergic disease in

the 90's: from allergic rhinitis to immune deficiency".

Highlights of a symposium held 11/7/89 at the annual meeting of the

Southern Medical Association, Washington, D.C.

15. Lockey RF: Participant, "Managing Myself: Learning to Live Well with Asthma", Foresight

Communications, Inc., Chicago, Illinois, 1994.

16. Lockey RF: “Immunotherapy: Now and in the Future”, Volume XXIV, educations Program

(CME) for Current Views in Allergy and Immunology, Current Views Inc., Atlanta, Georgia,

May 1996.

17. Lockey RF: “Update on Immunotherapy Vaccines”, Volume XXIX,

educational program for Current Views in Allergy and Immunology,

Medical College of Georgia, Augusta, Georgia, November 2000.

18. Lockey RF: “Allergic Rhinitis and Asthma”, Volume 36 Issue 18, Audio-Digest

Otolaryngology, September 21, 2003.

19. Lockey RF: “Asthma and Comorbidities”Volume 40, Program 4, Current Views in Allergy,

Asthma & Immunology, Presented by Medical College of Georgia at Georgia Health Sciences

University and Division of Continuing Education, 2012.

20. Lockey RF: Scientific Interviews with Experts, WAO TV, World Allergy Organization,

March, 2014:

World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the

Evidence Base”.

http://www.youtube.com/watch?v=D2s-61IZy7c

Impulse Oscillometry (IOS) is easier than spirometry for older asthmatic and

non-asthmatic subjects.

http://www.youtube.com/watch?v=DOY8p0Q6QVU

Radiocontrast media reactions: Rectifying misconsptions about shellfish

allergy and iodine “allergy”.

http://www.youtube.com/watch?v=_hTVW3oc5ZA

https://webmail.health.usf.edu/owa/redir.aspx?C=buweHATWX06EoD97RyecgHMnAcxEF9EI_Dh1LPkDd798E-VQW_vSbBXTCBixQa-9BKOdk30Ucv4.&URL=http%3a%2f%2fwww.youtube.com%2fwatch%3fv%3dD2s-61IZy7c

https://webmail.health.usf.edu/owa/redir.aspx?C=buweHATWX06EoD97RyecgHMnAcxEF9EI_Dh1LPkDd798E-VQW_vSbBXTCBixQa-9BKOdk30Ucv4.&URL=http%3a%2f%2fwww.youtube.com%2fwatch%3fv%3dDOY8p0Q6QVU

https://webmail.health.usf.edu/owa/redir.aspx?C=buweHATWX06EoD97RyecgHMnAcxEF9EI_Dh1LPkDd798E-VQW_vSbBXTCBixQa-9BKOdk30Ucv4.&URL=http%3a%2f%2fwww.youtube.com%2fwatch%3fv%3d_hTVW3oc5ZA

57

NETWORK

SEGMENTS:

1. Exam Room Network (ERN) Segments, Medical News on:

Allergies News Storyboard: “Cat allergy”, February 26, 2003.

Asthma News Storyboard: “Heartburn”, February 26, 2003.

Heartburn News Storyboard: “Nasal”, February 26, 2003.

2. Exam Room Network (ERN) Segments, Medical News:

Asthma News Storyboard: “Sulfites”, April 17, 2003.

EXHIBITS:

1. Rhoades R, Buren W, Lockey R, Wittig H:

The imported fire ant.

Scientific Exhibit,

The American Academy of Allergy Annual Meeting, 1974.

2. Rhoades R, Buren W, Lockey R, Wittig H:

The imported fire ant.

Florida Medical Association Annual Meeting, May 1974,

(awarded third prize).

3. The American Academy of Allergy Committee on Insects.

The Hymenoptera Venom Study. State of the Art.

Monograph on human insect reactions.

Scientific Exhibit, The American Academy of Allergy Annual Meeting, February

1980.

1

RESEARCH

STUDIES:

Title PI Date Status Sponsor Funds IRB #

[protocol no. SARCA]

The Study of Acid Reflux in

Children with Asthma (SARCA)

Lockey 2009 Closed -

PI

American Lung

Association

105583

[protocol no. APR]

Asthma Patient Registry

Lockey 09/14/2009 Approved,

Open

American Lung

Association

108273

Repeated Nasal Challenge in Skin

Prick-Puncture Negative, Intradermal

Positive Dust Mite Allergic Rhinitis Patients


Open

Division Sponsored 106217

[protocol no. SOYA]

The Study of Soy Isoflavones in Asthma

Lockey 2010 Approved,

Open

American Lung

Association

Pro00000006

[protocol no. STAN]

Study of Asthma and Nasal Steroids


Open

American Lung

Association

Pro00000009

[protocol no. LASST]

Long Acting Beta Agonist Stepdown

Study (LASST)

Lockey Pending American Lung

Association

Pro00007478

Calcium Intake in Children on Inhaled or

Intranasal Corticosteroids

Lockey Submission

review in

progress

Pending Division Sponsored

Pro00006255

Obesity & Asthma: Genetics and

Nutrigenetic Response to Omega-3 Fatty

Acids


Open

National Institute of

Health

Pro00006491

Effect of Oxymetazoline Hydrochloride in

Combination with Nasal Glucocorticoid on

the Apnea Hypopnea Index (AHI), nocturnal

oxyhemoglobin saturation, snoring, and

sleep quality in Subjects with Persistent

Nasal Congestion.


Open

Division Sponsored

Pro00001844

Identification of Plasma miRNAs as

Potential Biomarkers in Asthma

exacerbation


Open

Division Sponsored

Pro00005011

USF CRU COMPREHENSIVE STUDY LIST

https://arc.research.usf.edu/Prod/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b6751D8B99F6AA74BBBB374F30573F3E9%5d%5d

https://arc.research.usf.edu/Prod/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5bFF609433FCFBF0499829E6D9460F041B%5d%5d



https://arc.research.usf.edu/Prod/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5bF0A5D8F37B9AC24DA8499180D25B954E%5d%5d






https://arc.research.usf.edu/Prod/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b713013A3B87CFD41B38B581A693BCA5F%5d%5d



2

Myeloid Suppressors in Inflammation Lockey 9/18/2012 Closed- PI Division Sponsored

Pro00001787

Procalcitonin Level as a Diagnostic Aid in

Acute

Bacterial Sinusitis

Lockey 4/2/2012 Closed -

PI

Division Sponsored

106936

[protocol no. PO4230]

A Randomized, 26-Week, Placebo-

Controlled Efficacy and Safety Study with a

26-week Long Term Safety Extension, of

High- and Medium-Dose Inhaled

Mometasone Furoate/Formoterol Fixed-

Dose Combination Formulation Compared

with Formoterol and High-Dose Inhaled

Mometasone Furoate Monotherapy in

Subjects with Moderate to Severe COPD


PI

Schering-Plough

Corporation

105348

[protocol no. XRG5029C/3503]

A Randomized, Multicenter, Double-Blind,

Placebo-Controlled, Parallel Group Study of

the 12 Month Effect of Treatment with Once

Daily Triamcinolone Acetonide

(NASACORT® AQ Nasal Spray 110 ug) on

the Growth Velocity of Children, 3 to 9

Years of Age, with Perennial Allergic

Rhinitis (PAR)


PI

Sanofi-Aventis 105347

Oxymetazoline Hydrochloride in

Combination with Nasal Glucocorticosteroid

for Perennial Allergic and Non-Allergic

Rhinitis in Subjects with Persistent Nasal

Congestion


PI


[protocol no. D5896C00022]

A 52-Week, Randomised, Double-Blind,

Parallel-Group, Multi-Centre, Phase IIIB

Study Comparing the Long Term Safety of

SYMBICORT pMDI 160/4.5 ug x 2

Actuations Twice Daily to Budesonide HFA

pMDI 160 ug x 2 Actuations Twice Daily in

Adult and Adolescent (>- 12 Years) African

American Subjects with Asthma


PI

AstraZeneca Ltd. 105669

https://arc.research.usf.edu/Prod/Rooms/DisplayPages/LayoutInitial?Container=com.webridge.entity.Entity%5bOID%5b11AD085A2E73C64D9EEFABDCD297FD56%5d%5d

3

[protocol no. MK 0476-377]

A Double-Blind, Placebo-Controlled,

Multicenter, Crossover Study to Evaluate

the Effects of a Single Oral Dose of

Montelukast, Compared with Placebo, on

Exercise-Induced Bronchoconstriction (EIB)

in Pediatric Patients Aged 4 to 14 Years


PI

Merck & Company,

Inc.

107559

Effect of Supplemental Oral Curcumin in

Patients with Atopic Asthma


PI


Interleukin-13 in Chitin Allergic, Steroid

Non-Responsive Moderate to Severe

Asthmatics


PI


[protocol no. PGX003]

A Phase I, Randomized Crossover, Double-

Blind, Placebo-Controlled Pilot Study

Evaluating the Safety of Apadenoson Use in

Subjects with Moderate to Severe Chronic

Obstructive Pulmonary Disease (COPD)


PI

PGxHealth, LLC 108074

[protocol no. PGX002]

A Phase I, Randomized Crossover, Double-

Blind, Placebo-Controlled Pilot Study

Evaluating the Safety of Apadenoson Use in

Subjects with Mild to Moderate Asthma


PI

PGxHealth, LLC 108083

[protocol no. MeCIS]

Methacholine Bronchoprovocation -

Influence of High Potency Inhaled

Corticosteroids in Asthma (MeCIS)


PI

American Lung

Association

107044

[protocol no. QAB149B2349]

A 12 Week Treatment, Multi-Center,

Randomized, Parallel Group, Double Blind,

Double Dummy Study to Assess the

Superiority of Indacaterol (150 ug o.d.) via a

SDDPI in Patients with Moderate to Severe

COPD, using Salmeterol (50 ug b.i.d.) as an

Active Comparator Delivered via a DISKUS

Inhaler


PI

Novartis

Pharmaceutical

Corporation

107560

[protocol no. MK-0633-007]

A Double-Blind, Randomized, Placebo-

Controlled, Multicenter, Parallel Group,

Dose-Ranging Study of MK-0633 in Adult

Patients with Chronic Asthma


PI

Merck & Company,

Inc.

106358

4


A Randomized, Double-Blind, Placebo-

Controlled, Parallel-Group Study,

Conducted Under In-House Blinding

Conditions of MD-0633 in Patients with

COPD


PI

Merck & Company,

Inc.

106370

[protocol no. ADC111891]

An Evaluation of Lung Function and

Symptoms in Patients with Chronic

Obstructive Pulmonary Disease (COPD) on

Long-Acting Bronchodilator Monotherapy


PI

GlaxoSmithKline 107394

Naturalistic Studies of Parental Permission

and Assent for Research


PI

Nemours Foundation 107349

[protocol no. MK-0633-007 Extension]

A Double-Blind, Placebo-Controlled

Extension to the Study of MK-0633 in Adult

Patients with Chronic Asthma (Extension to

Protocol 007)


PI

Merck & Company,

Inc.

107287

[protocol no. CQAB149B2335S]

A 26-Week Treatment, Multicenter,

Randomized, Double-Blind, Double Dummy,

Placebo-Controlled, Adaptive, Seamless,

Parallel-Group Study to Assess the Efficacy,

Safety and Tolerability of Two Doses of

Indacaterol (Selected from 75, 150, 300 &

600 ug o.d.) in Patients with Chronic

Obstructive Pulmonary Disease Using

Blinded Formoterol (12 ug b.i.d.) and Open

Label Tiotropium (18 ug o.d.) as Active

Controls CQAB149B2335S


PI

Novartis Foundation 105704


A 52-Week Efficacy and Safety Non-

Interiority Study of Fluticasone

Propionate/Salmeterol 250/50 mcg BID

Delivered by Dry Powder Inhaler (Diskus)

Versus Mometasone Furoate/Formoterol

Fumerate 200/10 mcg BID Delivered by

Pressurized Metered-Dose Inhaler in

Persistent Asthmatics Previously Treated

with Medium Doses of Inhaled

Glucocorticosteroids PO4705


PI

Schering-Plough

Corporation

105722

5

Topical Antibiotic Use in Chronic

Rhinosinusitis, a Double-Blinded,

Randomized, Placebo Controlled Study


Expired

USF Asthma, Allergy

& Immunology

106811

Altana Pharma [protocol no. BY217/M2-

124]

Effect of roflumilast on exacerbation rate in

patients with COPD. A 52-week, double-

blind study with 500 mcg roflumilast once

daily versus placebo


PI

Altana Pharma 104723

[protocol no. ADA109057]

A 52-Week, Randomized, Double-Blind,

Parallel-Group Study of Fluticasone

Propionate/Salmeterol DISKUS

Combination Product (FSC) 250/50 mcg

BID and Fluticasone Propionate (FP)

DISKUS 250 mcg BID in Treatment of

Subjects with Asthma


PI

Glaxo SmithKline 105618

[protocol no. SKY2028-3-004]


Controlled, Parallel Group, Stratified,

Multi-Center, 12-Week Study Comparing

the Safety and Efficacy of Fluticasone and

Formoterol Combination (FlutiForm

100/10ug or 250/10ug twice daily) in a Single

Inhaler (SkyePharma HFA pMDI) with the

Administration of Placebo or Fluticasone

(250ug twice daily) and Formoterol (10ug

twice daily) Alone in Adolescent and Adult

Patients with Moderate to Severe Asthma


PI

Skye Pharma, Inc. 105273

Association of Atrial Natriuretic Peptide

Gene Polymorphism and Asthma Severity


PI


[protocol no. M05-757]

A Phase 2a, Multicenter, Randomized,

Double-Blind, Placebo-Controlled Parallel

Study to Evaluate the Safety, Efficacy and

Pharmacokinetics of Adalimumab in

Subjects with Refractory Asthma, Protocol

M05-757


PI

Abbott Laboratories 106070

Predicting the Diagnosis of Asthma Based on

History


PI


6

[protocol no. CIGE025AUS23]

A 26-Week, Randomized, Double-Blind,

Parallel-Group, Placebo-Controlled, Multi-

Center Study to Evaluate the Effect of

Xolair (omalizumab) on A 26-Week,

Randomized, Double-Blind, Parallel-Group,

Placebo-Controlled, Multi-Center Study to

Evaluate the Effect of Xolair (omalizumab)

on Improving the Tolerability of Specific

Immunotherapy in Patients with at Least

Moderate Persistent Allergic Asthma

Inadequately Controlled with Inhaled

Corticosteroids - CIGE025AUS23


PI

Novartis

Pharmaceutical

Corporation

104336

The Use of Topical Antibiotics in Chronic

Rhinosinusitis


Expired


[protocol no. OPL104226]

A Prospective Observational Study for the

Psychometric Validation of a Patient-

Reported Questionnaire in Acute

Exacerbations of Chronic Obstructive

Pulmonary Disease (AECOPD) -

OPL104226


PI


[protocol no. SLIT03-04]

Safety and Dosing Study for Sublingual-

Oral Administration of Standardized

Glycerinated Cat Hair Allergenic Extract -

SLIT03-04


PI

Greer Laboratories,

Inc.

103315

[protocol no. SB207499, CIL103657]

A Randomized, 24-week, Double-Blind,

Placebo-Controlled, Parallel-Group Study to

Evaluate the Efficacy, Safety and

Tolerability of ARIFLO® (15mg BID) in

Patients with Chronic Obstructive

Pulmonary Disease (COPD)


PI


[protocol no. SIRNA]

Sinusitis and Rhinitis in Asthma (SIRNA)


PI

American Lung

Association

104152

7

[protocol no. SFA 100062]

A Randomized, Parallel Group, Double-

Blind, Comparative Trial Assessing Lung

Function and Other Measures of Asthma

Control in Adults and Adolescents, at Least

12 Years of Age, with Persistent Asthma,

Who Have Either a B16-Arg/Arg, a B16-

Gly/Gly or a B-16 Arg/Gly Genotype and

are Treated with Fluticasone


Combination Product 100/50mcg or

Salmeterol DISKUS 50 mcg BID -

SFA100062


PI


Determination of a Specific Phenotype for

Asthma and Allergy


PI


[ALA protocol no. TAPE]

Effect of Education and Drug Presentation

on Efficacy of Montelukast and Placebo in

Asthma (TAPE)


PI

National Institutes of

Health/DHHS

101072

[protocol no. DX-88/5 EDEMA 2]

An Open Label Study to Assess the Efficacy

and Tolerability of Repeated Doses of DX-88

(recombinant plasma kallikrein inhibitor) in

Patients with Hereditary Angioedema - DX-

88/5


PI

Dyax Corp. 101852

[protocol no. SCO40043]

A Randomized, Double-Blind, Parallel

Group, 52-Week Study to Compare the

Effect of the Fluticasone


Combination Product 250/50mcg BID with

Salmeterol DISKUS 50 mcg BID on the

Annual Rate of Moderate/Severe

Exacerbations in Subjects with Chronic

Obstructive Pulmonary Disease (COPD)


PI


Impact of an Asthma Camp on Knowledge

and Clinical Outcomes


PI


[protocol no. DX-88/4]

An Ascending Four Dose Placebo Controlled

Study to Assess the Efficacy and Tolerability

of DX-88 (Recombinant Plasma Kallikrein

Inhibitor) Administered Following Onset of

Acute Attacks of Hereditary Angioedema


PI

Dyax Corp. 100778

8

Effect of Aging and the Effect of Sun

Damage on Allergy Skin Tests


PI


A Multi-Center, Multinational, Randomized,

Double-Blind, Parallel Group Study of the

Effects of Ciclesonide HFA-MDI 640

uG/Day and Beclomethasone HFA-MDI 640

uG/Day on Lens Opacification In Adult

Subjects with Moderate to Severe Persistent

Asthma


PI

Aventis

Pharmaceuticals

102142

[protocol no. SAM 40065]

A Multi-Center, Randomized, Double-Blind,

Parallel group, 40-Week Comparison of

Asthma Control Using Bronchial

Hyperresponsiveness As An Additional

Guide to Long-Term Treatment in

Adolescents and Adults Receiving Either

Fluticasone Propionate/Salmeterol Diskus

Bid or Fluticasone Propionate Diskus Bid

(or Placebo Bid if Asymptomatic)


PI


[protocol no. 197-01-210]

A Phase II, Multicenter, Randomized,

Double-Blind, Placebo-Controlled, Parallel-

Arm, Dose Comparison study of the Efficacy

and Safety of Oral 25mg, 50mg, 75mg OPC-

6535 and Placebo in the Treatment of


Pulmonary Disease


PI

Otsuka America

Pharmaceutical, Inc.

100034

[protocol no. ONO-6126POU011]

A Four Week, Double Blind, Placebo-

Controlled, Exploratory Evaluation of Fev

1.0 Changes and Safety of ONO-6126 in

Patients with Chronic, Obstructive



PI

Ono Pharma USA 101986

[protocol no. ANC-MD-17]

Double Blind Study of the Efficacy, Safety,

and Pharmacoeconomics of Flunisolide HFA

Inhaler System as Compared to Fluticasone

Inhalation Aerosol in Patients with Asthma


PI

Forest Lab. 100855

9

[protocol no. Q2196N]

An Observational Study of the Epidemiology

and Natural History of Asthma: Outcomes

and Treatment Regimens (Tenor)


PI

Genentech, Inc. 6063

Parietaria Floridana and Allergic Rhinitis in

the Tampa Bay Area


PI


International Study of Asthma and Allergies

in Childhood (ISAAC), Data from the West

Coast of Florida


PI

Asthma & Allergy

Foundation of

America (Florida)

101098d

[protocol no. MO16455P/3001]

A Multicenter, Double-Blind, Randomized,

Parallel Groups, Placebo-Controlled Study

to Assess the Efficacy and Safety of

Fexofenadine 120 MG BID in Subjects with

Mild to Moderate Persistent Asthma


PI

Aventis 100033

[protocol no. M016455P-3003]

A Multicenter, Open-Label, Randomized,

Parallel Groups Study to Assess the Long-

Term Safety Performance of Fexofenadine

Compared to Montelukast in Subjects with

Asthma


PI

Aventis 100032d

[protocol no. 340-72]

Efficacy and Safety of Monetasone Furoate

Dry Powder Inhaler in the Treatment of




PI

Schering-Plough

Corporation

5787

[protocol no. SAS 30028]

A Stratified, Randomized, Double-Blind,

Parallel-Group, Multi-Center, 96-Week

Study Evaluating the Growth Effects of

Fluticasone Propionate/Saimeterol DISKUS

Combination Product 100/50mcg Twice

Daily versus Usual Non-Corticosteriod

Maintenance Therapy in Pre-Pubescent

Pediatric Subjects with Asthma


PI


[protocol no. Merck 016-00]

A Double-Blind, Randoimized, Placebo-

Controlled, Multicenter, Parallel-Group,

Proof-of-Concept Study of L-000454560 in

Patients With COPD


PI

Merck & Company,

Inc.

101086c

10

12 Weeks Treatment with 250ug Roflumilast

versus Placebo in Patients with Asthma


PI

Altana, Inc. 6529d

Possible Allerginicity of Oak Acorns Lockey 10/31/2003 Closed -

PI

Division Sponsored 6518d

[protocol no. SAS40037]


Double-Dummy, Parallel-Group, 16-Week

Comparison of Asthma Control in

Adolescents and Adults Receiving Either

Fluticasone Propionate/Salmeterol

DISKUS® Combination Product 100/50mcg

BID, Fluticasone Propionate DISKUS®

100mcg BID, Salmeterol Xinafoate

DISKUS® 50mcg BID, or Oral Motelukast

100mg QD


PI

GlaxoSmithKline 6465c

[protocol no. SAM40066]


Double-Dummy, Placebo Controlled,

Parallel Group, Four-Week Study Assessing

the Efficacy of Fluticasone Propionate

Aqueous Nasal Spray 200mcg QD versus

Montelukast 10mg QD in Adolescent and

Adult Subjects with Asthma and Seasonal

Allergic Rhinitis Who are Receiving

Concurrent Open-Label ADVAIR DISKUS

100/50mcg BID


PI

GlaxoSmithKline 100577d

[protocol no. P01861]

A Placebo- and Active-Controlled Efficacy

and Safety Study of a Once-Daily Fixed

Combination Tablet of Desloratadine 5mg /

Pseudoephedrine 120mg (SCH 483 [5/120])

in Subjects With Seasonal Allergic Rhinitis


PI

Schering-Plough

Corporation

100611d

[protocol no. FAP 30010]

A Randomized, Double-Blind, Parallel-

Group, Placebo-Controlled 12-Week Trial of

Inhaled Fluticasone Propionate 88MCG BID

Versus Placebo in Propellant GR106642X in

Pediatric Subjects 4 to 11 Years of Age with

Asthma


PI


11

[protocol no. M016455M/3002 (PAR)]

A Multicenter, Double-Blind, Randomized,

Parallel Study Comparing the Efficacy and

Safety of Fexofenadine 120 mg BID,

Fexofenadine 240 mg QD, and Placebo in

Subjects with Perennial Allergic Rhinitis


PI

Aventis 100544

[protocol no. LODO]

Effectiveness of Low-Dose Theophylline as

Add-On Therapy in the Treatment of

Asthma ("The LoDo Trial")


PI

American Lung

Association

6356d

[protocol no. SD004-0111]

START-Inhaled Steroid Treatment As

Regular Therapy in Early Asthma: A Study

of the Effect of Early Intervention With

Long-Term Inhaled Budesonide

(Pulmicort(R) Turbuhaler(R)) in Newly

Diagnosed Asthma


PI


[protocol no. 309801]

A Phase 3 Study to Determine the Efficacy

and Safety of C1-Inhibitor (Human) Vapor

Heated, Immuno in Subjects with

Hereditary Angioedema (HAE)


PI

Baxter Healthcare

Corporation

5812

[protocol no. 07]

A Double Blind, Placebo Controlled, Long

Term Growth Study of HFA Flunisolide in

Children with Mild Asthma


PI

Forest Laboratories,

Inc.

5707

[protocol no. ANC-MD-09]

Double-Blind, Placebo Controlled, Parallel

Group Study of the Efficacy and Safety of

Once Daily Flunisolide HFA Inhaler System

in Patients with Asthma Currently Treated

with Inhaled Steroids


PI


Inc.

6103

[protocol no. SAVE]

URTI Symptom Score Pilot Study


PI

American Lung

Association

6603


Placebo Controlled Efficacy and Safety

Study of a Once-Daily PM and Twice Daily

Regimens of Mometasone Furoate

Administered Via Dry Powder Inhaler in

Subjects with Asthma Who Were Previously

Maintained on Inhaled Corticosteroids


PI

Schering-Plough

Corporation

6050

12


A Randomized, Double-Blind Study to

Determine the Efficacy of Levalbuterol

Versus Racemic Albuterol in the Treatment

of Acute Asthma


PI

Sepracor, Inc. 5969


Double-Dummy, Parallel Group, 8 Week

Comparison of Salmeterol Xinafoate Versus

Ipratropium Bromide Versus Salmeterol

Xinafoate Plus Ipratropium Bromide Versus

Placebo in Subjects With Chronic

Obstructive Pulmonary Disease


PI

Glaxo Wellcome, Inc. 5944

[protocol no. SMS40321]


Double-Dummy, Parallel-Group comparison

of Salmeterol Xinafoate Inhalation Aerosol

Versus Ipratropium Bromide and Albuterol

Sulfate Inhalation Aerosol in Subjects With

Chronic Obstructive Pulmonary Disease


PI


[protocol no. M016455A/4122]

A Double-Blind, Double-Dummy, Parallel-

Group, Multi-Center, Randomized Study of

Fexofenadine HCL 180 MG vs. Cetirizine

HCL 10 MG in Subjects with Moderate to

Severe Seasonal Allergic Rhinitis (SAR)

During the Fall or Winter/Spring Allergy

Season


PI

Aventis 6379

A Randomized, Double-Blind, Double

Dummy, Parallel Group Comparison of

Fluticasone Propionate Inhalation Powder

(50 mdg BID) via DISKUS® with Oral

Montelukast (5 mg QD) Chewable Tablets in

Children 6 to 12 Years of Age with

Persistent Asthma


PI



Controlled Study to Evaluate the Clinical

Efficacy, Virologic Activity, and Safety of

Pleconaril (Oral Suspension) in the

Treatment of Viral Respiratory Infection in

Children 1 to 6 Years of Age


PI

ViroPharma, Inc. 6388

13

[protocol no. 061/059]








PI


[protocol no. SIIVA]


Controlled, Crossover Trial of the Safety of

Inactivated Influenza Vaccine in Adults and

Children with Asthma


PI

American Lung

Association

5853

Qualitative Interview Regarding

Experiences on Bayer 19-8004 Trial


PI

Bayer Corporation 6290

The Efficacy of Disodium Octaborate

Tetrahydrate (DOT) and Vacuum Cleaning

in Lowering House Dust Mite Population

and House Dust Mite Allergen Levels in

Homes


PI



A Phase II, Randomized, Placebo-

Controlled, Double-Blind, Parallel Group,

Dose-Finding Study to Evaluate the

Effectiveness of 28 Days of Treatment with

LDP-977 in Adult Asthmatics


PI

Millenium

Pharmaceuticals, Inc.

6252

Rhinitis in Patients with Gastroesophageal

Reflux: Prevalence and Characterization


PI


A Twelve Month, Open Label Study of

Oxis™ Turbuhaler® in Adults and

Adolescents with Asthma


PI


[protocol no. ADVIL SAR-AD-99-02]

Advil Multi-Symptom Allergy Sinus Efficacy

and Safety Study


PI

Whitehall-Robins

Healthcare

6111

A Randomized, Double-Blind, Multicenter

Study to Evaluate the Effect of Adding

Either Montelukast Sodium or Salmeterol

Xinafoate to Inhaled Fluticasone in Adult

Asthmatics


PI

Merck & Company,

Inc.

5561

14

A Phase III, Multicenter, Double-Blind,

Parallel Group Study Assessing the Effects

of Triamcinolone Acetonide HFA-134A MDI

on Growth in Asthmatic Children


PI

Aventis 5486

[protocol no. C98-477]

Double-Blind Study of the Effects of One

Year of Treatment with Mometasone

Furoate HFA-227 Metered Dose Inhaler

(MF MDI) vs. Placebo on Growth of



PI

Schering-Plough

Corporation

5190

A Multicenter, Randomized, Double-Blind

Pilot Study Comparing the Clinical Effect of

Intravenous Montelukast with Placebo in

Patients with Acute Asthma


PI

Merck & Company,

Inc.

5750

Melaleuca Tree and Respiratory Disease Lockey 4/30/2001 Closed -

PI

Division Sponsored

5808

[protocol no. BAY 19-8004]


Group Comparison of the Safety and

Efficacy of Three Once Daily Doses of BAY

19-8004 with Placebo and Montelukast 10mg

Daily in Patients with Symptomatic Asthma


PI


[protocol no. 155] 1999


Controlled, Parallel-Group, Multicenter

Trial to Determine the Efficacy of Oral

Zafirlukast (ACCOLATE-TM) When

Administered According to Current

Labeling Instructions or Simplified Dosing

Instructions in Subjects with Asthma

Receiving Inhaled B2-Agonist Alone or

Inhaled B2-Agonist in Combination with

Inhaled Corticosteroids (ICS)


PI


Allergy to Ferret Lockey 2/28/2001 Closed -

PI



A Double-Blind, Randomized, Placebo- and

Active-Controlled, Multicenter, Parrallel-

Group, Dose-Ranging Study of L753099 in

Patients with COPD


PI

Merck & Company,

Inc.

15

[protocol no. 0476-074-00 Extension]

A Double-Blind, Randomized, Placebo-

Controlled, Multicenter, Crossover Study

Comparing Combination

Montelukast/Loratadine With Montelukast

and Loratadine Monotherapies in Patients

With Chronic Asthma


PI

Merck & Company,

Inc.

5528

[protocol no. P00355-18]

Efficacy and Safety of SCH 34117 +

Pseudoephedrine, BID, vs. its Components

in the Treatment of Subjects with Seasonal

Allergic Rhinitis


PI

Schering-Plough

Corporation

5475

Placebo-Controlled Efficacy and Safety

Study of Mometasone Furoate HFA-227

Metered Dose Inhaler (MF-MDI) in the

Treatment of Asthma in Children Previously

Maintained on Anti-Inflammatory Asthma

Medications


PI

Schering-Plough

Corporation

5173

[protocol no. FLTA 4039]


Group Comparison Study of Inhaled

Fluticasone Propionate (88mcg bid) Versus

Montelukast Sodium (10 mg QD) in Subjects

Currently Receiving Beta Agonists Alone


PI


[protocol no. SFCA 3006] 1998


Controlled, Parallel-Group, Trial

Evaluating the Safety and Efficacy of the

DISKUS Formulations of Salmeterol 50mcg

BID and Fluticasone Propionate 500mcg

BID Individually and in Combination as

Compared to Placebo in COPD Subjects


PI


Biological Standardization: The

Quantatative Skin Response in Subjects

Skin Tested with Varying Doses of Skin

Reactive Substances


PI

National Institutes of

Health/DHHS

5108

[protocol no. P00221]

Efficacy and Safety in the Treatment of

Chronic Idiopathic Urticaria (CIU) Subjects

with SCH 34117


PI

Schering-Plough

Corporation

5375

16


Phase IIA Multicenter, Randomized,

Double-Blind, Double-Dummy, Active and

Placebo-Controlled, Parallel Group, Dose-

Response Study of the Efficacy, Safety, and

Tolerability of Six Weeks Oral Dosing with

CJ-13,610 Compared to Montelukast and

Placebo in Adults with Persistent Asthma


PI

Pfizer, Inc. 5372

[protocol no. ANC-MD-04-000]

A One-Year, Open-Label Study to Evaluate

the Safety of HFA Flunisolide in Children

with Mild to Moderate Asthma


PI


Inc.

5042

A Multicenter, Double-Blind, Randomized

Study Comparing a Combination Tablet

Containing Montelukast + Loratadine with

Inhaled Beclomethasone in Patients with

Chronic Asthma


PI

Merck & Company,

Inc.

5025


Controlled, Parallel-Group 12-Week Trial

Evaluating the Safety and Efficacy of

Salmeterol/Fluticasone Propionate

Combination in GR106642X MDI,

50/250mcg BID, and Salmeterol in

Propellant 11/12 MDI, 50mcg BID,

Fluticasone Propionate in Propellant 11/12

MDI, 250mcg BID, and Placebo in

Propellant GR106642X MDI in Adolescent

and Adult Subjects with Asthma


PI

Glaxo, Inc. 5339

[protocol NKP608]

A Multicentre, Randomised, Double-Blind,

Parallel Group, Placebo-Controlled, Dose-

Ranging Trial to Assess the Efficacy and

Safety of NKP 608 Microemulsion Capsules

in Adult Patients with Chronic Bronchitis


PI

Novartis

Pharmaceutical

Corporation

5169

[protocol no. Formoterol 056)

Randomized, Double-Blind, Between-Patient

Trial Comparing Two Doses of Inhaled

Formoterol Fumarate Dry Powder (12 and

24 ug b.i.d.) with Placebo and Ipratropium

Bromide MDI (40 ug q.i.d.) for 12 Weeks in


Pulmonary Disease, in Terms of Clinical

Efficacy, Tolerability and Quality of Life


PI

Novartis

Pharmaceutical

Corporation

5152

17

A Comparison of the Effect of Two Doses of

Levalbuterol with Ventolin on Pulmonary

Function in Subjects with Mild to Moderate

Asthma


PI

Sepracor, Inc. 5084

A Double-Blind, Placebo-Controlled Study

to Evaluate the Effects of Treatment of

Seasonal Allergic Rhinitis (SAR) in Subjects

with Co-Morbid Asthma and a History of

Seasonal Exacerbations of Asthma on

Medical Resources Utilization (for Asthma

and SAR)


PI

Integrated

Therapeutics Group,

Incorporated

4962

[protocol no. L808, 065-011 #004]

A Multicenter, Double-Blind, Placebo-

Controlled Study Comparing the Clinical

Effect of Nebulized L-808,065 in Patients

with Chronic Asthma


PI

Merck & Company,

Inc.

5170

Understanding of Asthma Through

Educational Intervention


PI

Integrated

Therapeutics Group,

Incorporated

4534

[protocol no. RG5016T 310, Azmacort HFA

Study 204]

A Phase II/III Double-Blind, Placebo-


Efficacy, Safety and Dose Response Study of

Azmacort(R) (triamcinolone acetonide)

HFA-134a Inhalation Aerosol 225 mcg, 460

mcg and 900 mcg Administered Once Daily

for 12 Weeks in the Treatment of Mild

Persistent and Moderate Persistent Asthma

in 800 Adolescents and Adults


PI

Rhone-Poulenc Rorer

Central

Pharmaceuticals

4801

A Randomized, Open Label, Cross-Over

Study Comparing the Parent/Guardian

Preference for Montelukast Sodium Tablets

or Cromolyn Sodium Aerosol (MDI)

Treatment in their Children Ages 6 to 11

with Chronic Asthma


PI

Merck & Company,

Inc.

4437

18

Quantitative Intradermal Test Procedure to

Evaluate Subject Sensitivity to Euroglyphus

Maynei and Blomia Tropicalis House Dust

Mites and to Determine the Biological

Potency of Euroglyphus Maynei and Blomia

Tropicalis Using the ID50EAL Method - A

Single Center Trial


PI


Safety Evaluation of Once Daily Dosing of

Fexofenadine HCl 180 mg in Subjects with

Seasonal Allergic Rhinitis and Concomitant

Mild to Moderate Asthma


PI

Hoechst-Marion

Roussel, Inc.

5076

A comparative Study of the Efficacy and

Safety of Clarithromycin Immediate Release

Tablets and Loracarbef Pulvules for the

Treatment of Patients with Secondary

Bacterial Infection of Acute Bronchitis


PI

Abbott Laboratories 5106

A Repeat-Dose, Dose-Ranging, Placebo-

Controlled, Study of the Safety and Efficacy

of SB 210396 in Patients with Chronic

Severe Asthma


PI

Smithkline Beecham 4301

[protocol no. MK0476-031-20, extension]

An Open, Controlled Extension to the MK-

0476 versus Placebo Comparison Study to

Investigate the Long-Term Safety and

Tolerability of MK-0476 in Patients with

Chronic Asthma


PI

Merck & Company,

Inc.

3633

[protocol no. Accolate 9188IL-095 extension]


Placebo Controlled Trial of Zafirlukast

(Accolate) in Subjects With Mild to

Moderate Asthma: 3 Weeks Efficacy and Up

to 52 Weeks Open-Label Safety Extension


PI

Zeneca

Pharmaceutical Group

3959

Aerobid-Once-A-Day with AeroChamber in

Mild to Moderate Asthma Patients


PI


Inc.

4752

[protocol no. SLGA 4020] 1997

A Comparison of Salmeterol vs.

Theophylline vs. Salmeterol Plus

Theophylline in COPD Patients

(GlaxoWellcome)


PI


Treatment of Post-Viral Cough with

Beclomethasone


PI


19


A Multi-Clinic Double-Blind Randomized

Eighteen-Month Study in HIV-1

Seropositive Patients to Compare the

Efficacy and Safety of MK-639 (800 mg q 8

h) and Zidovudine (200 mg q 8 h)

Administered Concomitantly to MK-639

Alone and Zidovudine Alone


PI

Merck & Company,

Inc.

3791

A Randomized, Double-Blind, Double-

Dummy, Placebo-Controlled, Parallel-

Group, Comparative Study of Inhaled

Fluticasone Propionate (88mcg BID) Versus

Zafirlukast (20mg BID), in Subjects who are

Currently Receiving Beta-Agonists Alone


PI


12 Weeks Treatment with 250m g

Roflumilast versus 500mg Roflumilast

versus 10mg Montelukas versus Placebo in

Patients with Asthma

Lockey Closed -

Never

Opened

Byk Gulden

Pharmaceuticals

6075

12 Weeks Treatment with 250m g

Roflumilast versus 500mg Roflumilast

versus Placebo Added to 200mg Fluticasone

Propionate in Patients with Asthma

Lockey Closed -

Never

Opened

Byk Gulden

Pharmaceuticals

6076

A Double-Blind, Randomized, Placebo- and

Active-Controlled, Multicenter, Parallel-

Group, Dose-Ranging Study of L-753099 in

Patients With COPD

Lockey Closed -

Never

Opened

Merck & Company,

Inc.

5669







Lockey Disapprov

ed








Lockey Disapprov

ed


A Randomized, Placebo-Controlled Study of

the Safety and Immunologic Activity of a

Single-Dose of Subcutaneous Recombinant

Human Interleukin-12 (rhlL-12)

Administered Concurrently with Cat

Allergen in Patients Allergic to Cats


PI

Genetics Institute, Inc. 4708

20

A Randomized, Placebo-Controlled,

Ascending-Dose Study of the Safety and

Immunologic Activity of Nebulized

Recombinant Human Interleukin-12 (rhIL-

12) in Patients with Mild Asthma.

Lockey Closed -

Never

Opened

Genetics Institute, Inc. 5260

[protocol no. Aradigm 97-01] 1997

Effectiveness of the SmartMist Asthma

Management System Combined With

Inhaled Fluticasone Propionate vs.

Aerochamber with Fluticasone Propionate

in Moderate and Severe Asthmatics

(Aradigm 97-01 Ver. 4/30/97)

Lockey Closed -

PI

Aradigm Corporation 4572

Efficacy and Safety of Combination

Loratadine/Montelukast QD vs. its

Components in the Treatment of Subjects

with Seasonal Allergic Rhinitis

Lockey Closed -

Never

Opened

Schering-Plough

Corporation

5927

Efficacy and Safety of Combination

Loratadine/Montelukast QD vs. its

Components vs. Placebo in the Treatment of

Subjects with Seasonal Allergic Rhinitis

Lockey Closed -

Never

Opened

Schering-Plough

Corporation

5920

The Efficacy of Disodium Octaborate

Tetrahydrate (DOT) and Vacuum Cleaning

in Lowering Dust House Mite Population

and House Dust Mite Allergen Levels in

Homes in Tampa, FL

Lockey Closed -

Never

Opened


A 2-Week Double-Blind, Placebo-

Controlled, Parallel Group Study

Comparing the Anti-Inflammatory Effects

of Low, Medium, and High Dose

Mometasone Furoate/Formoterol Fumarate

MDI Formulation and Medium Dose

Mometasone Furoate DPI and MDI

Formulations in Adults and Adolescents

with Persistent Allergic Asthma

Lockey Closed -

Never

Opened

Schering-Plough

Corporation

106475

[protocol no. CQAB149B2329]

A 52-Week Treatment, Multicenter,

Randomized, Double-Blind, Placebo-

Controlled, Parallel-Group Study to Assess

the Efficacy, Safety and Tolerability of

Indacaterol (200 & 400 ug o.d.) in Patients

with Chronic Obstructive Pulmonary

Disease Using Open Label Tiotropium (18

ug o.d.) As An Active Control -

CQAB149B2329

Lockey Closed -

Never

Opened

Novartis

Pharmaceutical

Corporation

104337

21

A Comparative Double-Blind, Double-

Dummy Study of Desloratadine (DL) 4mg

Once Daily, Cetirizine 10mg Once Daily and

Placebo Once Daily in Patients with Chronic

Idiopathic Urticaria (CIU)

Lockey Closed -

Never

Opened

Integrated

Therapeutics Group,

Incorporated

102386

[protocol no. XRP1526B/3030]

A Multicenter, Randomzied, Double-Blind,

Placebo-Controlled, Parallel-Group Study to

Assess the Efficacy of Ciclesonide Metered-

Dose Inhaler at a Daily Dose of 160ug

Administered for 12 Weeks Either In A

Once-Daily Regimen in the Morning (160ug

qd AM) Or In A Twice Daily Regimen (80

ug bid) in Adults and Adolescents with Mild

to Moderate Persistent Asthma Treated

Previously With Inhaled Corticosteriods -

XRP1526B/3030

Lockey Closed -

Never

Opened

Aventis 103863

A One Week, Double-Blind, Randomized,

Placebo-Controlled Dose-Confirming Study

to Determine the Efficacy and Safety of

Oxis™ Turbuhaler® Administered to


Lockey Closed -

Never

Opened


A One Week, Double-Blind, Randomized,

Placebo-Controlled, Dose-Confirming Study

to Determine the Efficacy and Safety of

Oxis™ Turbuhaler® Administered to

Adults and Adolescents with Asthma

Lockey Closed -

Never

Opened


[protocol no. FFA109684]

A Randomized Double-Blind, Double

Dummy, Placebo-Controlled, Parallel-

Group, Multicenter Dose Ranging Study to

Evaluate the Efficacy and Safety of

GW685698X Inhalation Powder Once Daily

and Fluticasone Propionate Inhalation

Powder 500mcg Twice Daily Compared with

Placebo for 8 Weeks in Adolescent and

Adult Subjects with Persistent Asthma

Symptomatic on Moderate-Dose ICS

Therapy

Lockey Closed -

Never

Opened


22

[protocol no. FFA20003] 2006

A Randomized Double-Blind, Placebo-

Controlled, Parallel-Group, Multicenter,

Study to Evaluate the Efficacy and Safety of

GW685698X Inhalation Powder 200mcg,

400mcg, 600mcg and 800mcg Administered

Once Daily in the Morning and Fluticasone

Propionate 500mcg BID via DISCUS

Inhalation Powder Compared with Placebo

for 8 Weeks in Adolescent and Adult

Subjects (>=12 years old) with Persistent

Asthma Symptomatic on Moderate-Dose

ICS Therapy - FFA20003

Lockey Closed -

Never

Opened


[protocol no. FFA100240] 2006

A Randomized Double-Blind, Placebo-



GW685698X Inhalation Powder 25mcg,

50mcg, 100mcg and 200mcg Administered

Once Daily in the Morning and Fluticasone

Propionate 100mcg BID via DISKUS

Inhalation Powder Compared with Placeby

for 8 Weeks in Adolescent and Adult

Subjects (=12 years old) with Persistent

Asthma Symptomatic on NON-ICS Therapy

- FFA100240

Lockey Closed -

Never

Opened


[protocol no. BY217/M2-023]

A Randomized, Controlled Study of

Roflumilast (250 mcg and 500 mcg) versus

Placebo in Patients with Asthma


PI

Altana Pharma 102043

[protocol no. D5896C00001 D5 GEMINI]

A Randomized, Double-Blind, Active-

Controlled, Parallel-Group, Single-Dummy,

Multicenter, 12 Week Study to Assess the

Efficacy and Safety of SYMBICORT®

pMDI 160/4.5 ug x 2 Actuations Once-Daily

(QD) Compared to SYMBICORT pMDI

80/4.5 ug x 2 Actuations QD, SYMBICORT

pMDI 80/4.5 ug x 2 Actuations Twice-Daily

(BID) and to Budesonide pMDI 160 ug x 2

Acutations QD in Asthmatic Subjects 12

Years of Age and Older


PI


23

[protocol no. FFU105927] Never started


Controlled, Active Comparator, One-Week,

Cross-Oer, Multi-Center Study to Evaluate

the Efficacy and Experience of Once-Daily,

Intranasal Administration of 110mcg

Fluticasone Furoate Nasal Spray and 200

mcg Fluticasone Propionate Nasal Spray in

Adult Subjects with Seasonal Allergic

Rhinitis (FF105927)

Lockey Closed -

PI




Controlled, Parallel Group, Multi-Center,

Multiple Dose (7 days) Dose-Ranging Study,

To Assess the Efficacy and Safety of 4 Doses

of QAB149 (50, 100, 200 & 400 ug) Delivered

via a Multiple Dose Inhaler and 1 Dose of

QAB149 (400 ug) Delivered via a Single

Dose Inhaler in Patients with Chronic

Obstructive Pulmonary Disease (COPD) -

CQAB149B2205


PI

Novartis

Pharmaceutical

Corporation

102698

[protocol no. SKY 2028-004] 2008


Controlled, Parallel Group, Stratified,

Multi-Center, 12-Week Study Comparing

the Safety and Efficacy of Fluticasone and

Formoterol Combination (FlutiForm™

100/10ug or 250/10ug twice daily) in a Single

Inhaler (SkyePharma HFA pMDI) with the

Administration of Placebo or Fluticasone

(250ug twice daily) and Formoterol (10ug

twice daily) Alone in Adolescent and Adult

Patients with Moderate to Severe Asthma -

sky2028-004

Lockey Closed -

Never

Opened

Skye Pharma, Inc. 104408


Controlled, Parallel-Group, Multi-Center

Study to Evaluate the Effects of a One-Year

Course of Fluticasone Furoate Nasal Spray

110mcg QD on Growth in Pre-Pubescent,

Pediatric Subjects with Perennial Allergic

Rhinitis

Lockey Closed -

Never

Opened


24

[protocol no. FFR100010]




Once-Daily, Intranasal Administration of

GW685698X Aqueous Nasal Spray 50mcg

and 100mcg for 2 Weeks in Pediatric

Subjects ages 2 to <12 Years with Seasonal

Allergic Rhinitis (SAR)


PI


[protocol no. FFR30002]




Once-Daily, Intranasal Administration of

GW685698X Aqueous Nasal Spray 100mg

for 4 weeks in Adult and Adolescent

Subjects (=>12 years of age) with Perennial

Rhinitis


PI


[protocol no. SD-0040764]

A Randomized, Partly Blinded, Multicenter,

Parallel Study Comparing the Efficacy and

Safety of PULMICORT RESPULES®

(budesonide inhalation suspension) at 0.5

mg, QD, 1.0 mg QD, 1.0 mg BID, 2.0 mg BID

and PULMICORT TURBUHALER®

(budesonide) at 400 mcg BID in Adolescents

(12 Years of Age and Older) and Adults with

Moderate to Severe Asthma


PI


[protocol no. SFA100316]

A Stratified, Multicenter, Randomized,

Double-Blind, Parallel Group, 4-Week

Comparison of Fluticasone


Combination Product 100/50mcg BID versus

Fluticasone Propionate DISKUS 100mcg

BID in Pediatric and Adolescent Subjects

with Activity Induced Bronchospasm


PI


[protocol no. MRE0470P-203]

A Two-Part Study to Evaluate the Safety of

Binodenoson (MRE0470) in Adult Subjects

With Mild, Intermittent Asthma


PI

King Pharmaceuticals

Research and

Development, Inc.

101766

25

Phase I, Open-Label Investigation of Safety

and Pharmacokinetics of Lyophilized

Korean Green Cross Intravenous Immune

Globulin 5% Solution in Patients with

Primary Immunodeficiency Disorders

Lockey Closed -

Never

Opened

Unassigned 6102

Procalcitonin Level as a Diagnostic Aid in

Acute Bacterial Sinusitis

Lockey Closed -

Never

Opened

Default Sponsor 106964

[protocol no. A2-8397-CAT]

Prospective Validation Study of the Chronic

Obstructive Pulmonary Disease Assessment

Test (CAT) in Stable and Exacerbating

Patients

Lockey Closed -

Never

Opened


Rhinitis and Sinusitis in Asthma Lockey Closed -

Never

Opened

American Lung

Association

103260

[protocol no. SARA]

Study of Acid Reflux and Asthma (SARA)


PI

American Lung

Association

102756

Systemic Reactions in Allergen

Immunotherapy

Lockey 2008

Closed -

PI


The Leukotriene Modifier Or

Corticosteroids or Corticosteroid-Salmeterol

Trial (The LOCCS Trial)

Lockey 2005

Closed -

PI

American Lung

Association

100966

26

[protocol no. Formoterol 37-3027, proj. no.

843-32]

A double-blind, randomized, parallel-group,

placebo-controlled dose response study of

formoterol Turbuhaler 6, 12, and 24 mcg

administered twice daily in patients with

asthma

Lockey 1994 Closed Astra, USA 3428

HZA106853: A dose-ranging study of

vilanterol (VI) inhalation powder in children

aged 5-11 years with asthma on a

background of inhaled corticosteroid

therapy


Open


GB27862: A PHASE III, RANDOMIZED,

DOUBLE-BLIND, PLACEBO-

CONTROLLED STUDY TO ASSESS THE

EFFICACY AND SAFETY OF

LEBRIKIZUMAB IN PATIENTS WITH

UNCONTROLLED ASTHMA WHO ARE

ON INHALED CORTICOSTEROIDS AND

A SECOND CONTROLLER

MEDICATION


Open

Genentech (a member

of the Roche group)

20120172

SAS115359, a Safety and Efficacy Study of

Inhaled Fluticasone Propionate/Salmeterol

Combination versus Inhaled Fluticasone

Propionate in the Treatment of Adolescent

and Adult Subjects with Asthma


Open

GlaxoSmithKline

Research &

Development Limited

20112136

SAS115358: A 6-month safety and benefit

study of inhaled fluticasone propionate/

salmeterol combination versus inhaled

fluticasone propionate in the treatment of

6,200 pediatric subjects 4-11 years old with

persistent asthma


Open

GlaxoSmithKline

Research &

Development Limited

20111924

FFR101782: A Randomized, Double-Blind,

Placebo-Controlled, Parallel-Group, Multi-

Center Study to Evaluate the Effects of a

One-Year Course of Fluticasone Furoate

Nasal Spray 110mcg QD on Growth in Pre-

Pubescent, Pediatric Subjects with Perennial

Allergic Rhinitis

Lockey 2007 Closed GlxoSmithKline 20072255

HGT-FIR-086: A Multicenter, Open-Label,

Non-Randomized Study to Assess the

Pharmacokinetics, Tolerability, and Safety

of a Single Subcutaneous Administration of

Icatibant in Children and Adolescents with


Open

Shire Orphan

Therapies, Inc

20111381

27

Hereditary Angioedema

HGT-FIR-054: A Phase III Randomized

Double-blind, Placebo-controlled

Multicenter Study of Icatibant for

Subcutaneous Injection in Patients with

Acute Attacks of Hereditary Angioedema

(HAE)

Lockey 2009 Closed Jerini US, Inc. 20090365

A6631029: A PHASE II, RANDOMIZED,

DOUBLE-BLIND, PLACEBO-

CONTROLLED, PARALLEL GROUP

STUDY TO EVALUATE THE EFFICACY

AND SAFETY OF ONCE-DAILY

ORALLY ADMINISTERED PH-797804

FOR 12 WEEKS IN ADULTS WITH

MODERATE TO SEVERE CHRONIC

OBSTRUCTIVE PULMONARY DISEASE

(COPD) ON A BACKGROUND OF

SALMETEROL

ZINOFOATE/FLUTICASONE

PROPIONATE COMBINATION


Open

Pfizer Limited 20111229

HZC113782: A Clinical Outcomes Study to

compare the effect of Fluticasone

Furoate/Vilanterol Inhalation Powder

100/25mcg with placebo on Survival in

Subjects with moderate Chronic Obstructive

Pulmonary Disease (COPD) and a history of

or at increased risk for cardiovascular

disease


Open


FFA109684: A Randomized Double-Blind,

Double-Dummy, Placebo-Controlled,

Parallel-Group, Multicenter Dose Ranging




Powder 500mcg Twice Daily compared with



Symptomatic on Moderate-Dose ICS

Therapy

Lockey 2008 Closed GlaxoSmithKline 20080317

28

ACT11457: A randomized, double-blind,

placebo-controlled, parallel group study to

assess the efficacy, safety, and tolerability of

SAR231893/REGN668 administered

subcutaneously (SC) once weekly for 12

weeks in patients with persistent moderate

to severe eosinophilic asthma who are

partially controlled/uncontrolled by inhaled

corticosteroid (ICS) plus long-acting beta2

agonist (LABA) therapy


Open

Sanofi-aventis, US,

Inc.

20110248

C1 1310: A Phase IIIb randomized, double-

blind, placebo-controlled study with an

open-label extension evaluating the efficacy,

safety and immunogenicity of recombinant

human C1 inhibitor for the treatment of

acute attacks of angioedema in patients with

HAE


Open

Pharming

Technologies B.V.

20102041

[protocol no. C 1205-01]

C 1205-01: A randomized, placebo-

controlled, double-blind Phase II study of

the safety and efficacy of recombinant

human C1 inhibitor for the treatment of

acute attacks in patients with hereditary

angioedema

Lockey 2010 Closed Pharming

Technologies, B.V.

20051760

P06476: A Randomized, Evaluator-Blind,

Crossover, Single Dose Study of the

Bronchodilator Effect of Formoterol

Fumarate in Combination With

Mometasone Furoate Metered Dose Inhaler

Delivered With and Without a Spacer

Versus Placebo and Foradil® Aerolizer® in

Children With Persistent Asthma

Lockey 2010 Closed Schering Plough

Research Institute, a

Division of Schering

Corporation

20102021

[protocol no. MI-CP186]

A Phase 2, Multicenter, Randomized,

Double-blind, Placebo-controlled Study to

Evaluate the Safety and Efficacy of

Intravenously Administered MEDI-563, A

Humanized Anti-interleukin-5 Receptor

Alpha Monoclonal Antibody, on Asthma

Control Following Acute Exacerbations in

Adults

Lockey 2009 Closed MedImmune 20090964

29

[protocol no. 205.452]

A randomised, active-controlled, double-

blind, double-dummy, parallel group design,

multi-center trial to compare the efficacy

and safety of 2.5 μg and 5 μg Tiotropium

Inhalation Solution delivered by the

Respimat® Inhaler with Tiotropium

inhalation capsules 18 μg delivered by the

HandiHaler®

Lockey 2010 Closed Boehringer Ingelheim


20100683

[protocol no. 1184.15]

1184.15: A 24-week (+ 24 week extension),

randomized, placebo-controlled (only 1st 12-

week period), double-blind, parallel group,

efficacy and safety comparison of

Tiotropium/Salmeterol (7.5μg/25 μg)

Inhalation Powder in the morning (PE

capsule via tiotropium/salmeterol

HandiHaler®), Tiotropium (18 μg)

Inhalation Powder in the morning (gelatin

capsule via Spiriva®

HandHaler®),Salmeterol Inhalation (25 μg)

Powder in the morning and evening (PE

capsule via tiotropium/salmeterol

HandiHaler®) and Tiotropium/Salmeterol

(7.5 μg/25 μg) Inhalation Powder in the

morning (PE capsule via tiotropium

/salmeterol HandiHaler®) plus Salmeterol

(25 μg) Inhalation Powder in the evening

(PE capsule via tiotropium/salmeterol

HandiHaler®) in patients with COPD



20080635

[protocol no. A7881013]

A7881013: A PHASE 2B, PARALLEL,

DOUBLE BLIND, DOUBLE DUMMY,

ACTIVE COMPARATOR AND PLACEBO

CONTROLLED STUDY TO

INVESTIGATE THE SAFETY,

TOLERATION AND EFFICACY OF 6-

WEEK QD ADMINISTRATION OF PF-

00610355 CRC-749 DPI IN PATIENTS

WITH MODERATE COPD

Lockey 2010 Closed Pfizer 20100640


DX-88/24: A Phase 4, Long-Term

Observational Safety Study to Evaluate

Immunogenicity and Hypersensitivity with

Exposure to KALBITOR (ecallantide) for


Open

Dyax Corp. 20092375

30

the Treatment of Acute Attacks of HAE


DX-88/19: Patient Long Term Continuation

of DX-88 (Ecallantide) for acute Hereditary

or Acquired Angioedema Attacks

Lockey 2006 Closed Dyax Corp. 20062187


DX-88/14: Evaluation of DX-88’s Effects in

Mitigating Angioedema A double-blind,

placebo-controlled study followed by a

repeat dosing phase to assess the efficacy

and safety of DX-88 (recombinant plasma

kallikrein inhibitor) for the treatment of

acute attacks of Hereditary Angioedema

Lockey 2005

Closed Dyax Corp. 20052247

[protocol no. MI CP-143]

A phase 2A, randomized, double-blind,

placebo-controlled, dose-escalation study to

evaluate the safety and effect on exercise

challenge testing of multiple fixed

subcutaneous doses of MEDI-528, a

humanized anti-interleukin-9 monoclonal

antibody, in adults with stable asthma and

exercise-induced bronchoconstriction

Lockey 2009 Closed MedImmune 20080592


091-061: A Multicenter, Double-Blind,

Double-Dummy, Randomized, Active-

Controlled, Parallel Group Long-Term

Safety Study of 15 µg and 25 µg

Arformoterol Tartrate Inhalation Solution

BID in the Treatment of Subjects with


Lockey 2007 Closed Sepracor 20052090

[protocol no. ADA103578]

ADA103578: A multicenter, randomized,

double-blind, triple-dummy, placebo-

controlled, parallel group, four-week study

assessing the efficacy of fluticasone

propionate aqueous nasal spray 200 mcg QD

versus montelukast 10 mg QD in adolescent

and adult subjects with asthma and seasonal

allergic rhinitis who are receiving ADVAIR

Diskus 100/50 mcg BID or placebo BID


31


DX-88/20: A Randomized, Double-Blind,

Placebo-Controlled, Multi-Center Study to

Assess the Efficacy and Safety of DX-88

(Ecallantide) for the Treatment of Acute

Attacks of Hereditary Angioedema.

Lockey 2008

Closed Dyax Corp. 20062444

[protocol no. FFA109687]

FFA109687: A Randomized Double-Blind,

Double Dummy, Placebo-Controlled,

Parallel-Group, Multicenter, Dose Ranging




Powder 100mcg Twice Daily compared with



Symptomatic on Non-Steroidal Asthma

Therapy


[protocol no. B2C111045]

B2C111045: A Dose-Finding Study of

GW642444 versus Placebo in Patients with

COPD


[protocol no. MEE103219]

MEE103219: A randomized, double-blind,

parallel group clinical trial to assess safety,

tolerability, pharmacokinetics, and

pharmacodynamics of intravenous

mepolizumab (SB240563) (0.55mg/kg,

2.5mg/kg or 10mg/kg) in pediatric subjects

with eosinophilic esophagitis, aged 2 to 17

years


[protocol no. VAL-P-03-103] VAL-P-03-

103: Interview study to explore the content

validity of visual analogue scales to assess

severity of hereditary angioedema (HAE) in

adults in the USA and Italy

Lockey 2009

Closed Pharming

Technologies B.V.

20091584


CQAB149B2351: A randomized, double-

blind, controlled, parallel group, 12-week

treatment study to compare the efficacy and

safety of the combination of indacaterol

150μg once daily with open label tiotropium

18μg once daily in patients with moderate-

to-severe chronic obstructive pulmonary

disease

Lockey 2009 Closed Novartis

Pharmaceutical

corporation

20090658

32

[protocol no. SB 205312/070]

A multi-center, double-blind, placebo-

controlled, parallel group study to evaluate

the safety and efficacy of two doses of

SB205312 administered as an oral

suspension (75 mg BID and 150 mg BID) for

12 weeks in pediatric outpatients with

asthma

Lockey 1997 Closed SmithKline Beecham

[protocol no. LO269]

A double-blind, parallel, multicenter study

of the safety and efficacy of citirizine and

clemastine versus placebo in the treatment

of season allergic rhinitis in children

Lockey 1993 Closed Pfizer

[protocol no. P94-142-17]

A phase IV, double-blind, placebo-

controlled, double-dummy, comparison of

clinical efficacy and safety of Vanceril MDI

versus Azmacort MDI in adult asthmatics

Lockey 1995 Closed Schering

[protocol no. PDA-641/0805-A-205-US]

A comparison of the safety and efficacy of

two oral doses of PDA-641 10 mg and 30 mg

TID and placebo in mild to moderate

asthmatics

Lockey 1996 Closed Wyeth-Ayerst

[protocol no. MK 031-01]

A multicenter, double-blind, randomized,

parallel group study comparing the clinical

effect of MK-0476 and placebo in patient

with chronic asthma

Lockey 1994 Closed Merck Research

Laboratories

[protocol no. Rhinocort 05-3046-3047]

A randomized, open-label, comparison of

rhinocort budesonide aqua pump spray

versus NASALCROM (cromolyn sodium)in

treatment of children with perennial rhinitis

Lockey 1995 Closed Astra USA

[protocol no. M94199]

A long-term, surveillance study of Zileuton +

usual care versus usual care in patients with

asthma

Lockey 1995 Closed Abbott Laboratories

[protocol no. PJPR0053]

A double-blind, randomized study

comparing the efficacy and safety of

Fexofenadine and placebo in black patients

with seasonal allergic rhinitis

Lockey 1996 Closed Hoechst-Marion

Roussel, Inc.

33

[protocol no 9188IL-0029]

A multicenter, double-blind, placebo-

controlled study of Accolate in mild to

moderate asthmatic patients needing chronic

treatment 13-week efficacy and up to 1 year

open-label safety study extension

Lockey 1993 Closed ICI Pharmaceuticals

Group

[protocol no. FEPROO51]

A placebo-controlled, double-blind,

randomized, parallel study comparing

duration and action and safety and efficacy

of four dose strengths of Terfenadine in the

treatment of fall allergies

Lockey 1993 Closed Marion Merrill Dow,

Inc.

[protocol no. FLD-402]

A randomized, double-blind, double-

dummy, parallel-group comparative trial of

inhaled fluticasone propionate rotadisk via

Disk haler 250 mcg BID versus azmacort

oral inhaler 200 mcg QID versus placebo in

adolescents and adult subjects with

moderate chronic asthma

Lockey 1994 Closed Glaxo, Inc.

[protocol no. SLGA5013]

A randomized, double-blind, placebo-

controlled, parallel-group evaluation of the

effects of salmeterol on methacholine

induced bronchial hyperesponsiveness over

24-weeks in adolescents and adults subjects

with asthma

Lockey 1995 Closed GlaxoSmithKline

[protocol no. Miles]

A double-blind, randomized, placebo-

controlled trial in the safety and efficacy of

oral bay x 1005 100mg BID versus 250mg

BID versus 500mg BID versus placebo BID

for six-weeks in patients with asthma

Lockey 1994 Closed Bayer

[protocol no. Accolate 579394]

A multicenter, double-blind efficacy trial to

compare accolate given at 160mg per day

with placebo over 13-weeks in subjects with

chronic severe asthma

Lockey 1998 Closed Zeneca

Pharmaceuticals

[protocol 847]

A randomized, double-blind, parallel-

comparison of atrovent nasal spray 0.06%

and 0.12% 84mcg versus 168 mcg per nostril

respectively versus placebo BID in allergic

perennial allergic rhinitis


34


A clinical use study comparing nasalcrom

nasal solution 4% to placebo nasal solution

in treatment of the symptoms associated

with seasonal allergic rhinitis

Lockey 1995 Closed Wallace

[Protocol no. GS9310]

Quarterly long-term follow-ups on GS93107:

An open–label study of the safety and

efficacy of cidofovir for the treatment of

relapsing cytomegalovirus retinitis in

patients with AIDS

Lockey 1998 Closed GILEAD Sciences

[protocol no. SLGA 4004/4005]


dummy, comparative clinical trial of a 12-

week course of salmeterol xinafoate versus

ipratropium Bromide versus placebo PRN

ventolin in subjects with chronic obstructive

pulmonary disease

Lockey 1995 Closed Glaxo Wellcome

[protocol no. DFI2588, proj. no. 2446]

A multi-center, double-blind, placebo-

controlled, dose ranging study to assess and

compare the activity of an oral

administration FR27417-2.5, 10 and 30mg

once a day during 12 weeks in moderate

asthmatic patients

Lockey 1995 Closed Sanofi/Innovex, Inc.

[protocol no. V211-017-0030]

V211-017-0030: A Phase IIb Clinical Trial to

Evaluate the Safety, Tolerability and

Immunogenicity of Zoster Vaccine Live in

Patients on Chronic/Maintenance

Corticosteroids

Lockey 2010 Closed Merck & Co.


Terfenadine Urticaria Study

Lockey 1986 Closed,

destroyed

Merrill-Dow

[protocol no. 85-N-0039]

Cetirizine Urticaria Study

Lockey 1980 Closed,

destroyed

Pfizer

[protocol no. ANC-MD-07-000]

A One-Year, Open-Label Study to Evaluate

the Safety of HFA Flunisolide in Children

with Mild to Moderate Asthma

Lockey 1999 Closed Forest Research

Institute

35

[protocol no. MO16455/4092]

The effects of once daily dosing of

fexofenadine HCl in patients with seasonal

allergic rhinitis and concomitant mild to

moderate asthma

Lockey 2002 Closed Hoechst Marion

Roussel

[protocol no. C94-092-11]

Safety and Efficacy of Mometasone Furoate

Nasal Spray vs. Placebo in the treatment of

Elderly patients with Perennial Rhinitis

Lockey 1994 Closed Schering-Plough

Corporation


5-Lipoxygenase Inhibitor Zileuton (Abbott-

64077): A Phase II Study on the Safety and

Efficacy of Zileuton (ABBOTT-64077),

800mg B.I.D. or 600mg Q.I.D. versus

Placebo in the Treatment of Moderate

Asthma

Lockey 1990 Closed Abbott Laboratories


The Efficacy of SCH 37224 in Mild to

Moderate Asthma

Lockey 1988 Closed Schering Corp.

[protocol no. 888-201-3]

A Multicenter, Double-Blind, Three Month

Study of the Comparative Efficacy and

Safety of Procaterol and Albuterol Aerosol

Administered QID in Outpatients with

Reversible Bronchial Airway Obstruction

Lockey 1989 Closed Parke-Davis

Pharmaceutical

1685

[protocol no. RG-5003-601]

A Multi-Center, Single-Blind, Randomized,

Parallel Study Evaluating the Safety and

Efficacy of a Once-A-Day Evening Dosing of

SLO-BID™ Gyrocaps® (theophylline,

anhydrous) vs. Theo-Dur® Tablets

(theophylline, anhydrous) B.I.D. in the

Treatment of Nocturnal Asthma

Lockey 1993 Closed Rorer Pharmaceutical

Corporation

[protocol no. AU-115, Ridaura]

Auranofin versus Placebo in the Treatment

of Steroid-Dependent Asthma

Lockey 1989 Closed Smith Kline & French

Laboratories

36

[protocol no. 9188IL/0028]


Study to Compare the Effect of Oral Doses

of ICI 204,219 with Placebo Over 13 weeks

in Subjects with Mild to Moderate Asthma

Lockey 1992 Closed Zeneca

Pharmaceuticals

Group

[protocol no. SLGA 4004/4005]


dummy, comparative clinical trial of a 12-

week course of salmeterol xinafoate versus

ipratropium Bromide versus placebo PRN

ventolin in subjects with chronic obstructive

pulmonary disease

Lockey 1995 Closed GlaxoSmithKline

[protocol no. 01029]

Randomized, Multiple-Dose, Double-Blind

Comparison of COMBIVENT® and

Ventolin® in a Four Week, Parallel Study in

Patients With Chronic Obstructive



[protocol no. 120-01/SNG 477]

A Randomized. Double-Blind, Multicenter

Study to Evaluate the Effect of Adding

Either Montelukast Sodium or Salmeterol

Xinafoate to Inhaled Fluticasone in Adult

Asthmatics

Lockey 2000 Closed Merck & Co.

[protocol no. M/5900/0003]

The treatment of AIDS associated cachexia

patients with halotestin tablets

Lockey 1992 Closed Upjohn Company

[protocol no. BW825]

Burroughs Wellcome Study

Lockey 1984 Closed Burroughs Wellcome

Double-blind parallel study (Rotcap Study)

and subcutaneous injectable study

Lockey 1984 Closed Glaxo

[protocol no. AI414-144]

Multicenter, Three-Arm, Comparative

Study of Cefprozil 250mg BID or 500mg

BID versus Amoxicillin/Clavulanate

Lockey 1993 Closed Bristol Myers Squibb

37

potassium 500mg TID in the treatment of

Acute and Uncomplicated Maxillary

Sinusitis

[protocol no. UNX-2405]

A Comparison of the Safety and Efficacy of

the 2 Immune Globulin Intravenous Human

Preparations (Unigam and Gammar ID) in

Primary Immunodeficiency Patients

Lockey 1993 Closed Univax Biologics

2881

Bronkometer

Isoepharine Six-Week Trial of Pediatric

Asthmatic Patients PD-663

Lockey 1986 Closed Sterling Winthrop

[protocol no. SEPR0051]

A placebo-controlled, double-blind,

randomized, parallel study comparing the

duration of action in safety and efficacy of

four dose strengths of Terfenadine in the

treatment of fall allergies

Lockey 1993 Closed Marion Merrill Dow

[protocol no. FLI-301]

A randomized, double-blind, comparative

trial of two doses of inhaled Fluticasone

Proprionate and Placebo in Adolescent and

Adult Patients with Mild to Moderate

Asthma

Lockey 1990 Closed Glaxo SmithKline

[protocol PHR-305]

A double-blind, double-dummy, parallel

group evaluation of the clinical equivalent of

albuterol aerosol delivery through the

standard BK300 valve or through the

redesigned BK356 valve


Cetirizine

A double-blind, parallel, multicenter study

of the safety and efficacy of Cetirizine 5mg

versus Cetirizine 10mg versus Astemizole

10mg in the treatment of Seasonal Allergic

Rhinitis

Lockey 1992 Closed Pfizer

[protocol no. RG5016-112]

An efficacy trial, comparable plasma

concentrations of Triamcinolone acetonide

given by inhalation (Azmacort) and

intramuscular injection (Kenalog-40) in the

management of moderate asthmatics

Lockey 1989 Closed Rorer

38


Proventil Repetabs for the prevention of the

nocturnal symptoms of asthma

Lockey 1992 Closed Schering Plough

[protocol no. FLTA 4031]


dummy, placebo-controlled, parallel group,

comparative study of inhaled fluticasone

proprionate 88mcg BID versus Zafirlukast

20 mg BID in subjects who currently

receiving beta agonists alone

Lockey 1997 Closed Glaxo Wellcome

[protocol no. SMART, SMG 477]

A randomized, double-blind, multicenter to

evaluate the effect of adding either

montelukast sodium or salmeterol xinafoate

to inhaled fluticasone on adult asthmatics

Lockey 2000 Closed Merck

[protocol no. SLGA 5007]

A double-blind, parallel group evaluation of

salmeterol versus placebo in the treatment of

nocturnal asthma


[protocol noABS-AS-304]

A 12-week comparison of the efficacy and

safety and steady-state Pharmacokinetics of

albuterol Spiromax® and placebo in

subjects 12 years and older with persistent

asthma with steady state pharmacokinetics

assessments

Lockey

2012

Closed

Teva Pharmaceuticals

20122022

[protocol no. VR506/2/004]

A randomized double-blind, parallel group,

dose-ranging study to evaluate the efficacy

and safety of three different total daily doses

of fluticacasone propionate inhaled from a

new dry powder inhaler in subjects with

severe persistent asthma requiring oral

corticosteroid therapy

Lockey

2012

Open

Vectura Limited

(Vectura”)

20121078

39

[protocol no. OPN-FLU-NP-3101]

A 16-Week Randomized Double-Blind,

Placebo-Controlled, Parallel-Group,

Multicenter Study Evaluating the Efficacy

and Safety of Intranasal Administration of

100, 200, and 400 μg of Fluticasone

Propionate Twice a Day (BID) Using a Novel

Bi-Directional Device in Subjects with

Bilateral Nasal Polyposis Followed by an 8-

Week Open-Label Extension Phase to Assess

Safety.

Lockey

2012

Open

OptiNose US, Inc.

20121023

[protocol no. KB003-04]

A Phase 2, Double-Blind, Placebo-

Controlled, Randomized Study to Evaluate

the Safety Tolerability, and Efficacy of

KB003 in Subjects with Asthma

Inadequately Controlled by Corticosteroids.

Lockey

2012

Closed

KaloBios


20120727

[protocol no. A6631033

A Phase 2B, Randomized, Double-Blind,

Double-Dynnt, Pkacevi-Controlled, Parallel

Group Study to Evaluate the Efficacy and

Safety of Once,-Daily Orally Administered

PH-797804 for 12 Weeks in Adults with

Moderate to Severe Chronic Obstructive

Pulmonary Disease (COPD) on a

Background of Tiotropium Bromide.

Lockey

2012

Closed

Pfizer, Inc/

20120635

[protocol no. HZA 106853]

A dose-ranging study of vilanterol (VI)

inhalation powder in children aged 5-

11years with asthma on a background of

inhaled corticosteroid therapy.

Lockey

2012

Open

GlaxoSmithKline

20120370

[protocol no. HZA SAS115359

A Safety and Effecacy Study of Inhaled

Fluticasone Propionate/Salmeterol

Combination versus Inhaled Fluticasone

Propionate in the Treatment of Adolescent

and Adult Subjects with Asthma.

Lockey

2011

Open

GlaxoSmithKline

Research &

DevelopmentLimited

20112136

40

[protocol no. SAS115358]

A 6-Month Safety and Benefit Study of

Inhaled Fluticasone Propionate/Salmeterol

Combination Versus Inhaled Fluticasone

Propionate in the Treatmnet of 6,200

Pediatric Subjects 4-11 years Old with

Persistent Asthma.

Lockey

2011

Open

GlaxoSmithKline Research &

DevelopmentLimited

20111924

[protocol no. HGT-FIR-086]

A Multicenter, Open-Label, Non-

Randomized Study to Assess the

Pharmacokinetics, Tolerability, and

Safety of a Single Subcutaneous

Administration of Icatibant in Children and

Adolescents with Hereditary Angioedema

Lockey

2011

Open

Shire Orphan Therapies, Inc.

20111381

[protocol no. A6631029]

A Phase II, Randomized, Double-Blind,

Placebo-Controlled, Parallel Group Study to

Evaluate the Efficacy and Safety of Once-

Daily Orally Administered PH-797804 for 12

Weeks in Adults with Moderate to Severe


(COPD) on a Background of Salmeterol

Xinofoate/Fluticasone Propionate

Combination.]

Lockey

2011

Closed

Pfizer Limited

20111229

[protocol no. HZC113782]

A Clinical Outcomes Study to Compare the

Effect of Fluticasone Furoate/Vilanterol

Inhalation Powder 100/25 mcg with Placebo

on Survival in Subjects with moderate

Chronic Obstructive Pulmonary disease

(COPD) and a History o for at Increased

Risk for Cardiovascular Disease.

Lockey

2011

Open

GlaxoSmithKline

20110383

[protocol no. C1 1310]

A Phase IIIb Randomized, Double-Blind,

Placebo-Controlled Study with an Open-

Label Extension evaluating the Efficacy,

Safety and Immunogenicity of Recombinant

Human C1 Inhibitor for the Treatment of

Acute Attacks of Angioedema in Patients

with HAE.]

Lockey

2010

Closed

Pharming Technologies B.V.

20102041

[protocol no. MI-CP220/D3250L00001]

A Phase 2b, Dose-Ranging Study to Evaluate

the Efficacy and Safety of MEDI-563 in

Adults with Uncontrolled Asthma.

Lockey

2010

Closed

Medimmune, LLC, an

affiliateof AstraZeneca AB

20101198

41


A Phase 4, Long-Term Observational Safety

Study to Evaluate Immunogenicity and

Hypersensitivity with Exposure to

KALBITOR (ecallantide) for the Treatment

of Acute Attacks of HAE.

Lockey

2009

Closed

Dyax Corp.

20092375

Rev. 01/06/14

Documents

Transcript of Rev. 01/06/14